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Disease
Abstract
Repeat expansion mutations in the gene C9orf72 are the most common cause of the fatal
neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD).
The molecular mechanisms that contribute to these diseases are still not fully understood. In this
dissertation, we explore mechanisms associated with repeat expansions in C9orf72 that alter gene
expression and contribute to disease. In chapter 2, we develop a novel method of targeted DNA
methylation in order to study how epigenetic changes in C9orf72 expansion carriers contribute to disease
pathways. We find that C9orf72 promoter hypermethylation is sufficient to reduce gene expression and
induce heterochromatin silencing of this locus in ALS patient derived cells. We also uncover a link
between DNA damage repair pathways and DNA methylation where a double strand break in CpG islands
can promote DNA methylation. Furthermore, we have taken advantage of these findings to develop and
optimize a novel targeted DNA methylation method that utilizes homology directed repair for precise
methylation editing in the absence of off-target effects. In chapter 3, we ask whether intermediate length
repeat expansions in C9orf72 are associated with a different neurodegenerative disease, corticobasal
degeneration (CBD). CBD shares similar clinical symptoms with Parkinson’s disease but exhibits distinct
tau pathology in neurons and glial cells. We find that intermediate C9orf72 repeat expansion carriers
(17-30 repeats) are three times more likely to develop CBD than those with smaller repeats. While full
expansion carriers with ALS/FTD tend to have reduced C9orf72 expression, we show that intermediate
expansion carriers actually have increased C9orf72 mRNA and protein levels. This increase in C9orf72
expression drives aberrant gene expression profiles in vesicle trafficking, stress response and autophagy
pathways. Furthermore, we find that autophagy initiated by nutrient starvation is deficient in cells that
over-express C9orf72. In sum, this thesis contributes a novel method of targeted DNA methylation to the
research community and shows how DNA methylation alters expression of a disease relevant gene. This
work also highlights how variable lengths of the repeat expansion in C9orf72 can lead to distinctive
underlying molecular mechanisms and ultimately drive risk for different neurodegenerative diseases.
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ABSTRACT
GENETIC AND EPIGENETIC MODIFIERS OF C9ORF72 EXPRESSION IN
NEURODEGENERATIVE DISEASE
Christopher P. Cali
Edward B. Lee

Repeat expansion mutations in the gene C9orf72 are the most common cause of the fatal
neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration
(FTD). The molecular mechanisms that contribute to these diseases are still not fully understood.
In this dissertation, we explore mechanisms associated with repeat expansions in C9orf72 that
alter gene expression and contribute to disease. In chapter 2, we develop a novel method of
targeted DNA methylation in order to study how epigenetic changes in C9orf72 expansion
carriers contribute to disease pathways. We find that C9orf72 promoter hypermethylation is
sufficient to reduce gene expression and induce heterochromatin silencing of this locus in ALS
patient derived cells. We also uncover a link between DNA damage repair pathways and DNA
methylation where a double strand break in CpG islands can promote DNA methylation.
Furthermore, we have taken advantage of these findings to develop and optimize a novel
targeted DNA methylation method that utilizes homology directed repair for precise methylation
editing in the absence of off-target effects. In chapter 3, we ask whether intermediate length
repeat expansions in C9orf72 are associated with a different neurodegenerative disease,
corticobasal degeneration (CBD). CBD shares similar clinical symptoms with Parkinson’s disease
but exhibits distinct tau pathology in neurons and glial cells. We find that intermediate C9orf72
repeat expansion carriers (17-30 repeats) are three times more likely to develop CBD than those
with smaller repeats. While full expansion carriers with ALS/FTD tend to have reduced C9orf72
expression, we show that intermediate expansion carriers actually have increased C9orf72
mRNA and protein levels. This increase in C9orf72 expression drives aberrant gene expression
profiles in vesicle trafficking, stress response and autophagy pathways. Furthermore, we find that
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autophagy initiated by nutrient starvation is deficient in cells that over-express C9orf72. In sum,
this thesis contributes a novel method of targeted DNA methylation to the research community
and shows how DNA methylation alters expression of a disease relevant gene. This work also
highlights how variable lengths of the repeat expansion in C9orf72 can lead to distinctive
underlying molecular mechanisms and ultimately drive risk for different neurodegenerative
diseases.
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Chapter 1: Introduction
Genetics of amyotrophic lateral sclerosis and frontotemporal degeneration

Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) are
fatal neurodegenerative diseases with clinical and genetic overlap1,2. ALS is a progressive
motor neuron disease selectively affecting both upper and lower motor neurons resulting
in muscle atrophy and death generally within 2-4 years after onset3. FTD is a disease that
preferentially affects the frontal and temporal cortex in which cortical neurons degenerate
resulting in language, memory and behavioral deficits4. Although age of onset for ALS
and FTD are similar (usually 50-60 years old), patients with FTD can live 10+ years after
disease onset5. Additionally, ALS and FTD clinical symptoms can co-occur in the same
patient3. These diseases can be classified by whether they have a known genetic etiology.
For instance, familial or hereditary disease is typically caused by a recognized genetic
mutation that adheres to classic Mendelian inheritance patterns. Sporadic forms of
ALS/FTD, on the other hand, usually do not have known disease-linked mutations and
typically do not follow defined inheritance patterns in families, although they can still
have a genetic component6–8.
Sporadic ALS accounts for up to 90% of total ALS cases6. To date, several loci
have been reproducibly associated with sporadic ALS, but these explain only a small
percentage of the underlying genetic etiology9. These include an association within an
intron of UNC13A, a gene involved in neurotransmitter realease10–12. Another association
has been identified near the gene SARM111,13, the protein product of which has been
shown to promote axonal degeneration in mice14. These associations occur in non-coding
1

regions, and thus it is still not clear whether the closest genes to the associated
polymorphisms are actually those underlying ALS risk. Two loci that do have rare amino
acid changes in sporadic ALS patients, however, have recently been identified11,12. These
include polymorphisms found in C21orf2 and KIF5A11,12. The function of C21orf2
however, is not yet clear, but it may be involved in DNA repair pathways and cilia
development15,16. KIF5A is a microtubule-associated molecular motor that is known to
function in neuronal pathways such as synaptic transmission, and knockout of the gene in
mice leads to epilepsy17. Thus, KIF5A represents an interesting candidate gene to explore
further. Finally, all major ALS genome-wide association studies identified variants in a
region on chromosome 9, which were later found to be a risk haplotype associated with
the carriers of a mutation in the gene C9orf7211–13,18. Mutations in C9orf72 will be
discussed in more detail in later sections.
As for sporadic FTD, there have only been a few identified genetic risk factors,
perhaps due the clinical and neuropathological heterogeneity of this disease19–23. The first
identified association was with TMEM106B19,23, a membrane bound protein involved in
lysosomal pathways24. Variants in TMEM106B were later implicated as disease modifiers
in patients with familial FTD caused by GRN or C9orf72 mutations, thus connecting this
genetic association with known disease mechanisms25–27. Other associations include
variants near the HLA locus and a locus encompassing RAB38 and CTSC21. Additionally,
variants in the ALS risk gene UNC13A have also been associated with FTD2. Several
other associations have been reported but have not yet been validated in replication
cohorts28.
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Much progress has been made in determining genetic causes of familial ALS and
FTD. Approximately 30 genes have been implicated in familial ALS, with the most
frequent being mutations in C9orf72 and SOD129. SOD1, which encodes copper-zinc
superoxide dismutase, is an antioxidant enzyme that normally functions to reduce cellular
superoxide levels to prevent free radical induced damage30. There are over 160 known
mutations in SOD1, which account for 20% of all familial ALS cases6. Mutated SOD1
protein forms insoluble aggregates in mitochondria that can be detected in patient spinal
cord and may be the cause of neurotoxicity31,32. Mutations in TARDBP, which encodes
the RNA binding protein TDP-43, are also a cause of familial ALS and account for
approximately 4% of familial ALS cases33. Mutations in TARDBP are notable because
TDP-43 protein aggregates are a hallmark of sporadic ALS as well34. Mutations in
another RNA binding protein, FUS¸ is also linked to familial ALS and these mutations
account for 3% of cases6. While rare, mutations in FUS and TARDBP implicate RNA
metabolism as a key disease pathway in ALS35.
The most frequently mutated genes that cause familial FTD include C9orf72,
MAPT, and GRN22. MAPT mutations, which encode the microtubule associated protein
tau, account for 10-20% of familial cases36. Carriers of MAPT mutations have unique
pathology in that they develop hyper-phosphorylated tau aggregates in the brain rather
than TDP-4331. Tau aggregation is thought to be neurotoxic and is implicated in a host of
other neurodegenerative diseases such as Alzheimer’s disease, corticobasal degeneration,
Pick’s disease and progressive supranuclear palsy37. Mutations in GRN account for 520% of familial FTD cases and result in TDP-43 brain pathology36. GRN mutations are
thought to cause disease through loss of function of the progranulin protein, which
3

normally may be involved in the inflammatory response to neuronal damage38. There are
also additional very rare mutations that cause FTD in genes such as VCP, TBK1,
CHMP2B and TARDBP36. Most of these rare mutations also lead to TDP-43 pathology22.
Identification of the C9orf72 repeat expansion mutation
The most recently discovered and the most common mutation underlying both
ALS and FTD (~30-50% of familial cases) occurs in the gene C9orf726. This locus was
first identified as contributing to ALS and FTD by linkage analysis of large families that
showed an autosomal dominant inheritance pattern for ALS and/or FTD39,40. The
susceptibility region on chromosome nine was further refined by genome-wide
association studies in European populations, which led to the discovery of a 42 variant
haplotype block spanning three genes that segregated with disease risk41,42. The casual
gene and mutation, which consisted of a G4C2 microsatellite repeat expansion in C9orf72,
was discovered in 201143,44. The hexanucleotide repeat expansion sequence can repeat
hundreds to thousands of times within the first intron of the gene45. Several studies have
attempted to find genetic or epigenetic factors that may determine whether a C9orf72
expansion carrier develops ALS verses FTD, but these have largely been
inconclusive46,47. To better understand the underlying pathogenic mechanisms of the
C9orf72 repeat expansion, it’s important to consider related neurodegenerative diseases
that are also caused by microsatellite repeat expansions.
Microsatellite repeat expansions and disease
Microsatellite repeat expansion diseases are a group of hereditary
neurodegenerative diseases caused by repetitive DNA elements that form large
4

expansions within exons, introns or untranslated regions48. The mechanism of
pathogenesis is often determined by the gene in which the expansion lies and the
sequence of the expansion itself (Figure 1.1).

Figure 1.1: Microsatellite repeat expansions and neurodegenerative disease. Genomic
locations and proposed mechanisms of repeat expansions that cause neurodegenerative diseases.
Expansions can occur in the 5’UTR, exon, intron or 3’UTR of over 20 genes. Repetitive RNA
from repeat expansions can lead to neuronal toxicity via sequestration of RNA binding proteins or
through toxic protein species. Additionally, repeat expansions that are close to the transcription
start site (TSS) can reduce expression of the gene in which they reside. Adapted from Liu, Cali and
Lee (2017)35; used under the Creative Commons Attribution License.

For instance, the CAG trinucleotide repeat in Huntington’s disease occurs within the first
exon of HTT, where it is translated into aggregation-prone polyglutamine protein, leading
to a toxic gain of function disease mechanism49. On the other hand, a CGG repeat in the
5’ untranslated region of FMR1 causes fragile X syndrome via epigenetic silencing and
reduction of the normal FMRP protein50. When a repeat expansion occurs within an
intron, however, the molecular pathogenesis is not as apparent. In Friedreich’s ataxia, for
example, an intronic GAA repeat reduces transcription of FXN and leads to
neurodegeneration via loss of function mechanisms51,52. However, an intronic CCTG
5

repeat in CNBP is thought to cause myotonic dystrophy type 2 via a toxic RNA gain of
function mechanism53. Thus, when the intronic hexanucleotide repeat expansion was
discovered within C9orf72, both a toxic gain of function mechanism and a loss of
function mechanism were proposed (Figure 1.2)43,44.

Figure 1.2: Proposed mechanisms of C9orf72 repeat expansion pathogenesis. A) An intronic repeat
expansion in C9orf72 (red box) is thought to cause disease through either loss of function or gain of
function mechanisms. C9orf72 has 3 mRNA isoforms (arrows represent transcription start sites) which give
rise to protein isoforms A and B. Only protein isoform A is detectable in human samples. B) Loss of
function mechanisms include decreased mRNA levels from expansion carriers (left panel) and increased
DNA methylation of the C9orf72 promoter (right panel), leading to haploinsufficiency of the C9orf72
protein. C) C9orf72 is involved in endosomal/lysosomal pathways. Interaction between C9orf72 and
autophagy initiation components ULK/ATG101 has been observed (left). Additionally, C9orf72 can bind
CARM1 to facilitate lysomal biogenesis (middle). C9orf72 also interacts with p62 to regulate stress granule
formation (right). D) Gain of function mechanisms include pathology derived from the repeat expansion
sequence such as RNA foci (left) and dipeptide repeat (DPR) aggregates (right). E) Repeat RNA foci
sequester RNA binding proteins and alter RNA splicing and nuclear transport (left). DPR aggregates are
thought to bind elongation initiation factor 3 (eIF3) and the ribosomal subunits, leading to global
translational dysregulation (right).
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Loss of function mechanisms of C9orf72 repeat expansions
In the years since the discovery of the C9orf72 repeat expansion, there have been
efforts to define the molecular mechanisms of C9orf72 expansion mediated
neurodegeneration. One proposed hypothesis was a loss function mechanism in which
reduced C9orf72 gene product resulted in haploinsufficiency of the normal protein
because reduced levels of C9orf72 mRNA and protein have been detected in repeat
expansion carriers43,44,54. Bioinformatic analysis of the primary amino acid sequence
revealed that C9orf72 is related to a class of proteins called Rab guanine exchange
factors, which are important regulators of vesicle trafficking55. Furthermore, the loss of
function hypothesis is supported by the finding that C9orf72 does regulate vesicle
trafficking and autophagy in neuronal cell lines56 and knockout in zebrafish results in
motor deficits57. However, the loss of function model does not fully account for the
results of studies using C9orf72 knockout mouse models.
In one mouse study, global deletion of C9orf72 resulted in several inflammatory
phenotypes including splenomegaly, lymphadenopathy and altered microglial and
macrophage function58. These mice, however, did not have neurodegenerative or
behavioral phenotypes that recapitulate ALS/FTD symptoms and lived a normal
lifespan58. In another study, C9orf72 knockout again caused splenomegaly as well as
inflammation that is consistent with autoimmune disease but no overt signs of
neurodegeneration59. In this study, however, complete knockout of C9orf72 severely
reduced lifespan, despite these mice being generated by the same methods as the
7

previously mentioned study59. A possible explanation for the difference in lifespan
between the two studies could be due to environmental factors such as diet, stress levels
or handling differences between the different institutions where the studies were
conducted. Another knockout mouse study also reported an autoimmune phenotype
consisting of myeloid expansion, T-cell activation and production of autoantibodies but
no neurodegeneration or ALS/FTD related phenotypes and normal lifespan60. All of the
C9orf72 knockout mouse models, however, exhibit aberrant immune system phenotypes
in only the homozygous knockout mouse but not in the heterozygous mouse58–60. Given
that almost all C9orf72 repeat expansion carriers are heterozygous for the expanded
allele61, the disease relevance of C9orf72 bi-allelic knockout mouse models are
questionable. Indeed, recent studies with novel antibodies or using mass spectrometry to
better quantify protein levels have shown that C9orf72 protein levels are only reduced by
~20-40% in ALS/FTD patients62,63. Furthermore, the effects seen in global C9orf72
knockout mice do not demonstrate how compromised immune system function would
interact with neuronal cells that are prone to degenerate in these diseases. To answer this
question, an additional mouse study used a conditional allele to knockout C9orf72
expression in only neurons and glial cells at embryonic day 10.5 onward64. This study
had the advantage of examining C9orf72 function in only disease relevant cell types and
after early developmental stages. The neuron/glial specific C9orf72 knockout mouse had
no signs of neurodegeneration and no indication of aberrant inflammation, suggesting
that the autoimmune effects observed in whole body knockouts were likely due to
C9orf72 functions in hematopoietic cells64. Overall, the animal models do show that the
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C9orf72 protein has biological functionality that is worth exploring, but its relevance to
neurodegenerative disease is not yet clear.
C9orf72 protein function and autophagy
The exact function of C9orf72 has been difficult to define, but it’s been suggested
that C9orf72 functions broadly in vesicle trafficking pathways such as the endosomallysosomal system and autophagy 65. The C9orf72 protein contains a region homologous
to the DENN (differentially expressed in neoplastic versus normal) domain, which allows
interaction with Rab GTPases to allow exchange of GDP with GTP and thus provide the
energy required for intracellular vesicle movement (Figure 1.3)66 .

Figure 1.3: Proposed functions of C9orf72 protein. C9orf72 is a DENN domain containing
protein that may function as a guanine exchange factor to provide energy for Rab GTPases, which
are involved in numerous vesicle trafficking pathways including intracellular trafficking, vesicle
secretion, stress granule assembly and autophagy. C9orf72 occurs in a complex with WDR41,
SMCR8 and various Rab GTPase proteins.
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Recent studies have shown that C9orf72 is capable of interacting with numerous Rab
GTPases (including Rab1a, Rab8, Rab39 and Rab7L1) that function at different steps of
the endo-lysosomal and autophagy pathways67–71. It is also well documented that C9orf72
occurs in a complex with the proteins SCMR8 and WD4172, and this complex interacts
with the ULK1 autophagy initiation complex67,69,73,74. However, whether C9orf72
normally promotes autophagy induction or reduces autophagic flux is still not
resolved67,69,74,75. This issue is complicated by the observation that C9orf72 functions
differently in response to nutrient stress than it does under normal conditions71,74 and also
has other related functions such as regulation of stress granules via autophagy76,77. The
complexity of C9orf72 function may be due to its ability to interact with many Rab
GTPases, which then can carry out diverse functions within these vesicle trafficking subpathways78. For instance, C9orf72 has been demonstrated to act as guanine exchange
factor (GEF) for Rab8 and Rab3968, but its closest homolog, folliculin, is a GTPaseactivating protein (GAP)79. GAPs and GEFs both regulate Rab GTPases that are
important for vesicle trafficking, but they do so through opposite mechanisms. GEFs
exchange GDP for GTP, thus activating the Rab GTPase for downstream signaling,
whereas GAPs stimulate GTP hydrolysis and inactivation of the target Rab GTPase79.
Given the homology to folliculin, it is possible that C9orf72 could have both GAP and
GEF activity depending on the target, although this has not yet been shown
experimentally. Additionally, the Rab GTPases that are targets of C9orf72 may change
depending on the cell type, conditions or stressors present. Thus, further study is needed
to define how C9orf72 functions in stress conditions and how the autophagy functions of
C9orf72 interact with the repeat expansion associated pathology.
10

Gain of function mechanisms of C9orf72 repeat expansions

The other major hypothesis for understanding the molecular mechanisms of
C9orf72 repeat expansions is that neurodegeneration results from toxic RNA and protein
species that are derived from the repeat expansion sequence80. Using fluorescent probes
against the repeat RNA, RNA “foci” were first observed in the nucleus of cortex and
spinal cord tissue from ALS/FTD patients43 and have since been observed in numerous
animal and cellular models81–85. Repeat RNA have been shown to bind and sequester
RNA binding proteins such as those involved in splicing and nuclear transport86–88.
Splicing factors that are possibly disrupted by the mutant RNA include hnRNP H and
SRSF286–88, whereas nuclear transport defects may be due to sequestration of ALYREF
and RanGAP1 by repeat expanded RNA86,89. This in turns leads to alterations in RNA
splicing pathways as well as defective nuclear transport of RNA87,90–93. This RNA
dysregulation model is attractive because defects in other RNA binding proteins such as
FUS and TDP-43 are established mechanisms of neurodegeneration35.
Another pathological hallmark of C9orf72 expansion carriers is the presence of
cytoplasmic protein aggregates that are generated from repeat RNA via the non-canonical
translation pathway known as Repeat Associated Non-AUG translation94–96. These
aggregates consist of chains of dipeptides which are translated from all reading frames of
the G4C2 repeat sequence in both the sense and antisense direction97. These dipeptide
repeat proteins (DPRs) are toxic in several model systems and proposed mechanisms of
neurodegeneration include impaired global translation pathways, impaired RNA
biogenesis, deficiencies in stress response pathways, and altered nucleocytoplasmic
transport98–103. Finally, all C9orf72 repeat expansion carriers develop cytoplasmic TDP11

43 aggregates, which is a hallmark of sporadic ALS and most forms of FTD34. TDP-43
normally resides in the nucleus, where it regulates RNA splicing, transport and stability34.
In ALS/FTD, TDP-43 is lost from the nucleus and aggregates in the cytoplasm, resulting
in thousands of gene expression changes in pathways such as RNA processing,
nucleocytoplasmic transport, histone processing, and DNA damage104. Thus, the toxic
nature of these three major pathologies (RNA foci, DPR and TDP-43) are thought to
underlay the gain of function model.
More experimental evidence for the gain of function hypothesis comes from
mouse models of C9orf72 expansion carriers that were generated either by Adeno
Associated Virus (AAV) delivery of G4C2 repeats or by insertion of the human repeat
expansion sequence via Bacterial Artificial Chromosome (BAC)105. Over-expression of
G4C2 repeats using AAV resulted in neurodegeneration, cognitive defects, RNA foci, and
both DPR and TDP-43 pathology84. AAV delivery of only a DPR encoding sequence
without the G4C2 RNA also induced motor and cognitive deficits in mice along with
characteristic pathology106, suggesting that DPRs alone are sufficient to cause ALS/FTDlike phenotypes. However, both of these methods drive pathology through overexpression at levels that are higher than observed in human disease84,106. Mice generated
using the human gene within a BAC construct, which represents a more physiological
model, also had characteristic RNA foci and DPR pathology85,107–109. While there were
differences between studies in the observed phenotypes, two studies reported cognitive
and motor defects in these mouse models108,109 and one reported sparse TDP-43
pathology109. Thus, expression of the repeat construct alone, without loss of normal
C9orf72 protein, is sufficient to recapitulate many features of ALS/FTD in mice.
12

In humans, however, it’s not yet clear which pathology (e.g. RNA foci, DPRs or
TDP-43 aggregation) are most responsible for driving neurodegeneration. TDP-43
aggregation is seen in regions of neurodegeneration in almost all ALS and FTD cases,
except for familial cases caused by rare mutations34. This suggests that TDP-43
aggregation is linked to neurodegenerative processes. Indeed, TDP-43 pathology
correlates more closely with neurodegeneration in C9orf72 expansion carriers than DPR
pathology does110. However, there have been several reports that FTD patients, including
some that died prematurely before end stage disease, can develop neurodegeneration in
the absence of TDP-43 pathology111,112. This has led to the idea that RNA foci and DPR
pathology may be an early event in disease progression, with TDP-43 aggregation
occurring later. Increased levels of DPR pathology has been reported to correlate with
earlier age of onset in both ALS and FTD cases113, suggesting that DPR aggregation may
initiate disease progression. Of note, ALS cases have never been found without TDP-43
pathology, suggesting that the contribution of these pathologies may differ between ALS
verses FTD114. Future studies will need to clarify how pathology derived from the repeat
expansion interacts with TDP-43 pathology and which of these is necessary for disease
progression.
A final consideration is that both a loss of function and gain function mechanism
together may contribute to pathogenesis. A study using induced motor neurons from ALS
patients suggests that a reduction in C9orf72 protein levels causes vesicle trafficking and
lysomal defects that make neurons more susceptible to DPR aggregates from the repeat
expansion115. This model presents a two hit hypothesis, where a loss of C9orf72
endosomal trafficking functions combine with toxicity from the repeat expansion
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sequence. Although this concept is not currently supported by data from available mouse
models, it is an interesting idea that should be further explored in future studies.
Intermediate repeat expansions in C9orf72
Repeat expansions in C9orf72 that cause ALS and FTD are usually hundreds to
thousands of units long, with an average length of approximately 1400-1600 G4C2 repeat
units in cerebellum45. Repeat expansions this large are almost fully penetrant, as
approximately 96% of carriers will develop either ALS or FTD before age 8045,116. The
minimum repeat number to develop ALS/FTD, however, has not been fully established.
There have been reports of small repeat sizes as low as 40-65 repeats in patients with
FTD117–119. However, there are issues that make accurate repeat sizing difficult including
somatic mosaicism within individuals, differences depending on the tissue collected and
technical challenges in accurately sizing a GC rich repetitive sequence45,117. A case report
of a cognitively normal individual with a repeat size of 30-40 units in cerebellum showed
that this length was enough to induce RNA foci and DPR pathology, but not TDP-43
pathology or clinical disease120. This was in contrast to a report indicating that a carrier
with 38 repeats in several brain regions developed ALS with TDP-43 pathology and
sparse DPR pathology121. Finally, another case report shows that an individual with an
average of 70 repeats (with some larger expansions in different brain regions) did not
develop clinical disease by age 90122. Thus, it appears that there is inter-patient variability
with regards to the minimum repeat length necessary to cause ALS/FTD, perhaps due to
differences in the genetic background or the degree of somatic mosaicism between
individuals. In general, it seems that repeat expansions less than 30 units do not cause
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ALS/FTD, whereas 30-70 repeats may represent a gray zone that depends on other
genetic and/or environmental factors. The majority (~70-80%) of non-diseased
individuals carry repeats of 2-8 units, whereas ~5% of the global population has repeat
sizes greater than 10 units123. Whether intermediate repeat expansions that are too small
to contribute to ALS/FTD but larger than normal (e.g. 10-30 units) are a risk factor for
other diseases remains an open question.
Several studies have examined the prevalence of intermediate C9orf72 expansions
in other neurodegenerative diseases. Intermediate expansions were completely absent in
Alzheimer’s disease119, but several studies reported small numbers of intermediate repeat
carriers with Parkinson’s Disease (PD)124,125. Interestingly, a follow up study that
investigated C9orf72 repeat length in only autopsy confirmed PD cases did not find any
intermediate or full expansions, suggesting discrepancies between clinically and
neuropathologically defined cohorts126. Finally, a large global meta-analysis of C9orf72
repeat length in PD patients found a significant but very minor association of PD with
intermediate length alleles (≥ 17 repeats) and concluded that the risk of developing PD
for intermediate carriers was negligible123. Thus, it is still not clear whether intermediate
repeat expansions in C9orf72 spanning 10-30 units are a risk factor for neurodegenerative
disease. Additionally, a recent study with a very small cohort examined C9orf72 repeat
sizes in autoimmune diseases and found a significant association between systemic lupus
erythematosus and intermediate repeats (9-30 units)127. While autoimmunity has been
implicated in C9orf72 knockout mice59, additional follow up studies will be necessary to
determine if there’s any biological significance of C9orf72 intermediate repeat
expansions in this context.
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Epigenetic alterations in microsatellite repeat expansion diseases
It is also important to consider epigenetic mechanisms of pathogenesis associated
with microsatellite repeat expansion disorders. DNA methylation is a covalent
modification of cytosine that is typically associated with transcriptional inhibition and is
carried out by several DNA methyltransferase enzymes (DNMTs)128,129. One important
function of DNA methylation is promotion of genome stability by silencing of repetitive
elements130,131. DNA methylation patterns are known to change during aging and in the
context of neurodegenerative disease132. Indeed, aberrant DNA methylation is a common
feature of microsatellite repeat expansion diseases and has been associated with myotonic
dystrophy, Friedreich’s ataxia and Fragile X syndrome 133–135. In the case of Fragile X,
the main driver of disease seems to be a loss of FMR1 expression that is associated with
DNA methylation of the upstream promoter135. Thus, epigenetic alterations are important
to understand the pathogenesis of repeat expansion mutations.
Changes in DNA methylation are also observed in C9orf72 repeat expansion
carriers. Approximately 33-36% of C9orf72 carriers gain DNA hypermethylation of the
promoter region, which is normally unmethylated in non-diseased individuals47,136–139.
Promoter hypermethylation was not significantly different between ALS and FTD
patients, but interestingly, hypermethylation correlates with longer survival in FTD
patients47. Hypermethylation also correlates with reduced RNA foci and DPR abundance
in patient tissue and patient derived cells137, indicating that C9orf72 promoter
methylation may be protective in the setting of the repeat expansion. Additionally, FTD
patients with promoter hypermethylation have reduced verbal recall decline over time
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and reduced grey matter volume loss as measured by MRI140. Why DNA
hypermethylation seems to be beneficial in FTD patients with the repeat expansion but
not ALS patients is an unresolved question. One possibility, as discussed previously, is
that TDP-43 pathology is driving neurodegeneration in ALS patients, whereas FTD
pathogenesis is may be more connected to repeat expansion pathology that is dependent
on C9orf72 expression. Additionally, why only a subset of patients develop
hypermethylation is also not clear. Studies to date have only applied correlative analysis
to study DNA methylation in C9orf72 carriers. To better understand these basic questions
and to define the causal mechanisms associated with DNA hypermethylation of C9orf72,
there is a need for disease models that accurately represent DNA hypermethylation as is
observed in C9orf72 repeat expansion carriers. Furthermore, an ideal model would be
generated via targeting DNA methylation in a controlled and specific fashion to the
C9orf72 promoter in patient derived cells. Such epigenetic editing experiments would
allow generation of isogenic cell lines that do not suffer from confounding factors due to
genetic background.
Methods of Epigenetic Editing

In the past decade, novel epigenetic editing tools have been developed that take
advantage of DNA binding proteins fused to epigenetic effector enzymes. These include
zinc finger proteins, TALE proteins and dead Cas9 proteins fused to DNA or histone
modifiers141. These fusion protein epigenetic editing tools have helped to define basic
cellular mechanisms142–149 and have been applied as potential therapeutics in diseases
with epigenetic alterations150,151. For targeted DNA methylation, a dead Cas9 enzyme
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fused to the catalytic domain of DNA methyltransferase 3a (dCas9-DNMT3a) was the
first tool generated using CRISPR/cas9152. CRISPR/cas9 based epigenetic editing
methods are attractive alternatives to zinc finger and TALE proteins due the low cost and
ease of multiplexing with guide RNAs (gRNAs) against various target loci141. However, a
major issue has emerged with dCas9 based DNA methylation editing tools concerning
specificity. Recent studies have observed that dCas9-DNMT3a tools can induce
thousands of off-target methylation changes153–155. Numerous off-target effects have also
been observed with dCas9 fused to cytosine base editing enzymes156. A possible
explanation of these off-target effects is that Cas9 is able to bind DNA sequences with
only a few base pairs of homology to the gRNA sequence, but requires more extensive
homology to initiate DNA cleavage157,158. Thus, dCas9 fusion proteins that only require
binding for DNA modification seem to initiate immensely more off-target changes than
traditional Cas9 applications that rely on DNA double strand breaks159. A newer DNA
methylation editing system has attempted to alleviate the off-target effects of dCas9
fusion proteins by using a modular system, called the SunTag system, to recruit DNMT3a
to the locus where dCas9 is bound155. The advantage of this system is that dCas9 is not
directly fused to DNMT3a and the amount of DNMT3a recruitment can be manipulated
by the expression levels of an antibody that binds the SunTag sequence155. However, this
system requires generation of multiple plasmids to target a single locus and the levels of
off-target effects are dependent on the amount of DNMT3a recruitment155. Thus, optimal
levels of the antibody encoding plasmid will need to be experimentally determined for
each application in order to prevent off-target target methylation.

18

DNA methylation and DNA repair pathways
While almost all available tools for epigenetic editing involve fusion protein
constructs, there is actually considerable evidence that DNA double strand break repair
pathways can alter DNA methylation. Numerous studies have demonstrated that DNMTs
are recruited to double strand break sites160–163. Upon double strand break, DNA can be
repaired either through the process of non-homologous end joining (NHEJ) or homology
directed repair (HDR)164. NHEJ occurs during G1 phase of the cell cycle and involves
recognition of the DNA break by the Ku complex, recruitment of the protein DNA-PKcs,
generation of overhangs by Artemis and finally ligation and fill-in by DNA
polymerases164. The polymerases used during NHEJ are error-prone, often resulting in
insertions or deletions (indels) at the repaired site164. Alternatively, the break can be
repaired using HDR, which is error free but occurs at lower frequency than NHEJ165.
HDR is a complex process that involves resection of the broken DNA ends, invasion of
the repair template and DNA synthesis using the repair template followed by ligation to
complete the newly copied DNA166.
Several studies have utilized fluorescent reporter DNA constructs to interrogate
whether DNA double strand breaks can induce DNA methylation. These studies show
that upon double strand break repair via HDR, a subset of the repaired DNA becomes
methylated, which leads to a reduction of reporter expression167–170. While there is some
disagreement between studies, methylation of the exogenous construct following DNA
repair appears dependent on DNMT1167, DNMT3a169 and UHRF1169, a protein
responsible for DNMT1 recruitment to hemi-methylated DNA171. Additionally, a double
strand break induced in a reporter construct that is repaired via NHEJ can also lead to
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DNA methylation172. Thus, it seems that DNA methylation is acquired following double
strand break regardless of the repair pathway that is utilized.
Objectives and Hypotheses
The overall objectives of this dissertation were to better understand the genetic
and epigenetic disease mechanisms underlying C9orf72 repeat expansions. In Chapter 2,
we aimed to generate a novel targeted DNA methylation technique that takes advantage
of the endogenous DNA double strand break repair pathways. We hypothesized that
double stranded breaks in the promoter CpG island of C9orf72 would facilitate
methylation near the break site. In the absence of repair template, the break would be
repaired with NHEJ, which would lead to localized DNA methylation along with indels
(Figure 1.4, left). In order to direct precise methylation editing, we asked whether an in
vitro methylated repair template could be supplied such that during HDR the methylation
marks would be copied from the exogenous repair template into the endogenous gene
(Figure 1.4, right).
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Figure 1.4: Proposed mechanisms of targeted DNA methylation via DNA double strand
break repair pathways. Double strand breaks are induced in a CpG island via CRISPR/cas9. In
the absence of repair template (left), the break is repaired via non-homologous end joining,
resulting in recruitment of DNA methyltransferases (DNMTs) to the break site and introduction
of localized DNA methylation. This pathway is also associated with insertions or deletions
(indels) near the break site. In order to direct precise methylation editing, an in vitro CpG
methylated template is provided (right) so that the break is repaired via homology directed repair.
During repair, UHRF1 is recruited to hemi-methylated DNA, which then recruits DNMTs to copy
methylation from the repair template into the endogenous sequence.

This would lead to templated methylation and should avoid the numerous off-target
effects observed with dCas9 fusion protein constructs. The final aim of chapter 2 was
then to apply this method, termed Homology Assisted Repair Dependent Epigenetic
eNgineering (HARDEN) to ALS/FTD patient derived cells with the C9orf72 repeat
expansion in order to generate a disease model of epigenetic dysfunction that’s observed
in patients. Using this model, we sought to directly test how DNA hypermethylation
affects C9orf72 expression and downstream pathogenesis.
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In Chapter 3, we aimed to determine the genetic and molecular mechanisms of
intermediate repeat expansions in C9orf72. Previous studies conflicted as to whether
intermediate repeats contribute to other neurodegenerative diseases such as Parkinson’s
disease (PD). We hypothesized that intermediate repeats in C9orf72 may be a risk factor
instead for corticobasal degeneration (CBD), a neurodegenerative disease that shares
clinical features with PD but has distinct pathological protein aggregates consisting of
tau173. In this study, we also sought to determine how intermediate repeats may affect
expression of C9orf72. We hypothesized that intermediate repeats may alter expression
differently than full repeat expansions that cause ALS/FTD. Finally, we sought to
uncover the molecular pathways that are affected in intermediate repeat carriers.
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Chapter 2: Targeted DNA methylation of C9orf72 via endogenous DNA
repair pathways
This chapter has been adapted from following manuscript, which is currently in revision at
Nucleic Acids Research, (Oxford University Press). Used under Creative Commons License

“Targeted DNA methylation of the ALS/FTD gene C9orf72 via endogenous DNA damage repair
pathways” by Christopher P Cali1, Daniel S Park1, and Edward B Lee1.
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Abstract
DNA methyltransferases (DNMTs) are thought to be involved in the cellular
response to DNA damage, thus linking DNA repair mechanisms with DNA methylation.
This study presents a novel method of targeted DNA methylation that utilizes
endogenous DNA double strand break repair pathways and applies it to the
neurodegenerative disease gene C9orf72. A double strand break induced by
CRISPR/cas9 in the promoter of C9orf72 is sufficient to induce DNA methylation, and
methylation can be precisely targeted through the process of homology directed repair
(HDR) via delivery of an in vitro methylated exogenous repair template. Long
methylated double stranded DNA templates induce more methylation than shorter
templates and with higher efficiency than a dCas9-DNMT3a fusion protein construct.
Genome-wide methylation analysis reveals no significant off-target methylation changes
when inducing methylation via HDR, whereas the dCas9-DNMT3a fusion construct
causes significant off-target methylation at over 67,000 sites. This method is applied to
generate a patient derived iPSC model of amyotrophic lateral sclerosis and
frontotemporal dementia (ALS/FTD) that exhibits stable DNA methylation patterns
similar to those seen in patients. Using this model, it’s shown for the first time that DNA
methylation of the 5’ regulatory region directly reduces C9orf72 expression and increases
histone H3K9 tri-methylation levels.
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Introduction
Methylation of cytosine is a chemical modification of DNA associated with a
myriad of regulatory processes in the mammalian genome such as regulation of gene
expression, stabilization of repeat elements, X-inactivation and maintenance of genomic
integrity128. Alterations in DNA methylation are associated with numerous diseases,
including cancer and neurodegenerative diseases such as those caused by expansion of
microsatellite repeat elements132. Aberrant methylation of the C9orf72 promoter region
has been observed in repeat expansion carriers with amyotrophic lateral sclerosis (ALS)
and frontotemporal dementia (FTD)47,137,139. In these patients, neurodegeneration is
caused by a repeat expansion in the first intron of C9orf72 which has been proposed to
cause production of toxic RNA and protein pathologies in patient tissue94, patient derived
cells81–83,98 and animal models84,85,88. Interestingly, hypermethylation of the promoter
occurs in ~1/3 of patients and correlates with increased survival time, reduced neuronal
loss and better verbal recall ability in FTD patients47,140. Thus, we hypothesize that
hypermethylation in the context of C9orf72 repeat expansions is neuroprotective.
However, to define causality between hypermethylation and disease pathology, there is a
need to generate isogenic patient derived cell lines that accurately model this epigenetic
aspect of ALS/FTD.
Current tools for targeted DNA methylation, such as the dead Cas9 (dCas9)–DNA
methyltransferase (DNMT) fusion protein152, have several features that limit their utility
for generation of epigenetic disease models. Recent studies have shown that the
methylation editing tools, such as the dCas9-DNMT3a fusion protein, have numerous
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off-target effects153–155,174,175, which may confound experiments or limit their use as
therapeutic agents. Another limitation with available tools is that these constructs are
usually large and difficult to transfect into patient derived primary cells or deliver via
gene therapy vectors for therapeutic purposes176 and they often require multiple gRNAs
to achieve robust activity152,174,175,177,178. Additionally, DNA methylation changes made
via the fusion protein constructs are often not maintained over numerous cell divisions at
some loci,148,152,153 making it difficult to generate stably edited cell lines for disease
modeling.
Due to these limitations, we sought to develop a novel method for epigenetic
editing that has fewer off target effects and enables generation of cellular disease models.
Development of this new system was based on the observation that endogenous DNMTs
are rapidly recruited to double stranded DNA (dsDNA) breaks160,161,163,168,169. For
example, when dsDNA breaks are induced in exogenous reporter DNA constructs, a
subset of cells gain DNA methylation of the exogenous construct, leading to gene
silencing167–170. Whether this acquired DNA methylation following break repair is unique
to exogenously expressed DNA or also occurs at endogenous loci is not yet known. We
sought to answer this question and furthermore to determine whether precise methylation
editing could be carried out via the process of homology directed repair (HDR) by
providing the cells with an in vitro generated repair template containing the methylation
marks to be copied into the genome. To our knowledge, no previous study has shown that
exogenous DNA methylation marks can be copied into an endogenous gene.
This study demonstrates that double stranded DNA breaks can directly induce
DNA methylation of the C9orf72 promoter and that methylation can be copied during
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HDR. These findings suggest that we have developed a novel method for editing DNA
methylation that takes advantage of the endogenous cellular repair machinery and does
not require over-expression of a methyltransferase enzyme. We term this method
Homology Assisted-Repair Dependent Epigenetic eNgineering (HARDEN) because
stable methylation editing is achieved upon DNA repair via HDR. This method exhibited
vastly fewer off-target effects than dCas9-DNMT3a fusion constructs and enables
generation of stably methylated cell lines that model epigenetic alterations seen in
neurodegenerative disease.

Methods
Plasmid and Repair template Generation
CRISPR gRNAs were designed using Benchling software (http://benchling.com/) and
cloned into pSpCas9(BB)-2A-Puro (PX459) V2.0 vector (Addgene, Cambridge, MA;
Plasmid #62988)) for HARDEN experiments or pdCas9-DNMT3A-PuroR (ANV)
(Addgene Plasmid #71684) and pdCas9-DNMT3A-PuroR_v2 (Addgene Plasmid
#74407) as previously described179. Single stranded oligonucleotide templates including
methylated oligonucleotides were synthesized by Integrated DNA Technologies, Inc.
(Coralville, Iowa). The non-homologous oligonucleotide template is homologous against
the unrelated gene EMX1. Sequences of gRNAs and templates are provided in
Supplemental Tables 2.1 and 2.2. Double stranded DNA templates were made by PCR
amplification of the target region using Q5 High Fidelity polymerase (New England
Biolabs, Ipswich, MA) according to the manufacturer’s protocol. 250ng of purified PCR
products were A-tailed in a reaction containing 0.25mM dATP, 1.5mM MgCl2, 1X
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Buffer II and 5U Amplitaq polymerase (Applied Biosystems, Foster City, CA) for 30
minutes at 70⁰ C. A-tailed PCR products were ligated into pGEM-T Easy vector
(Promega, Madison, WI) and transformed into NEB Turbo competent cells (New
England Biolabs) according to the manufacturer’s protocol. For introduction of PAM
mutations, site directed mutagenesis was carried out using the QuickChange XL kit
according to the manufacturer’s protocol (Agilent Technologies, Santa Clara, CA). Nonhomologous dsDNA templates consisted of the pGEM-T Easy vector without the
C9orf72 homologous region. For methylation of plasmid repair templates, 20ug of
plasmid DNA was methylated in a 100ul reaction containing 50U of M.SssI CpG
Methyltransferase (New England Biolabs), 640 µM SAM, 50 mM NaCl, 10 mM TrisHCl (pH 7.9) and 10 mM EDTA for 4 hours at 37⁰C. Enzyme was inactivated for 20
minutes at 65⁰ C and then plasmid DNA was purified via phenol chloroform extraction
followed by ethanol precipitation.

Cell Culture and Transfection
HEK293T cells were grown in DMEM high glucose + L-glutamine (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Flowery
Branch, GA) and 1X Penicillin/Streptomycin (Invitrogen). For transfection of CRISPR
components, 1μg Cas9/gRNA containing plasmid and 1μg repair template were cotransfected into 12 well dishes using Fugene 6 (Promega) or Lipofectamine 3000
(Invitrogen) with a 3:1 transfection to DNA ratio for 48 hours. For siRNA experiments,
cells were transfected with 40nM siRNA using Lipofectamine 3000 (Invitrogen). For
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time points longer than 2 days, puromycin selection was carried out at 1μg/mL for 3-4
additional days. For clonal line isolation, cells were diluted to 1cell/well in 96 well plates
7 days post transfection. DNA from clonal lines was isolated using QuickExtract Solution
(Lucigen, Middleton, WI) according to manufacturer’s protocol and screened for repair
with the template using PCR and restriction enzyme digest. Induced pluripotent cell line
CS52iALS-n6A was obtained from Cedars Sinai and maintained in mTeSR1 media
(Stem Cell Technologies, Vancouver, Canada) and grown on Matrigel matrix (Corning,
Corning, NY) coated plates as previously described81. For transfection of CRISPR
components, 750ng Cas9/gRNA plasmid + 750ng repair template was co-transfected into
12 well dishes using Viafect reagent (Promega) with a 4:1 transfection to DNA ratio for
48 hours. 0.5ug/mL puromycin was used for selection of transfected iPSCs.

Methylation sensitive restriction enzyme digest qPCR
Methylation sensitive restriction enzyme digest quantitative PCR (qPCR) was carried out
as previously described137. Genomic DNA was extracted using DNeasy Extraction kit
(Qiagen) and qPCR was carried out using FastStart Universal SYBR Green mastermix
(Roche, Basel, Switzerland) on a StepOne Plus Real-Time PCR Machine (Life
Technologies) using standard cycling. For measurement of methylation in samples
transfected with 1.4kb double-stranded templates, a forward primer was used that anneals
outside the repair template and the qPCR cycling conditions were modified (38 cycles,
annealing temperature 61.5 ⁰C, 1 min extension at 72⁰C) to increase specificity. %
methylation was calculated using the formula 2^(Ct Mock - Ct Digest). Fold change over
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controls was calculated for long amplicon qPCR because percent digest verses %
methylation is not 1:1. See Supplemental Table 2.1 for primers.

T7 Endonuclease Assay and HDR digest Assay
A T7 endonuclease assay was used to measure mutation (indel +HDR) efficiency based
on T7 digestion of mismatched DNA hybrids. Genomic DNA was PCR amplified using
Q5 hotstart polymerase (New England Biolabs), hybridized and digested with T7
Endonuclease I (New England Biolabs) according to manufacturer’s protocol. To
specifically measure HDR efficiency, 12ul of PCR product was digested with 8U SspIHF (New England Biolabs) in 1X Cutsmart buffer for 2 hours at 37⁰ C. Digest products
were run on either 2% agarose gels for T7 assay or 8% polyacrylamide gels for HDR
assay and stained with SYBR Gold (Invitrogen). Bands were quantified using
GelAnalyzer 2010a software (http://www.gelanalyzer.com/index.html) using valley to
valley background subtraction. For calculating T7 digest efficiency, we used the formula:
% digest = 100 x (1 – (1- fraction cleaved)1/2) as described previously180. For the
restriction enzyme HDR assay: % digest = (sum digested products) / (undigested +
digested products).

Bisulfite Cloning
1ug of genomic DNA was bisulfite converted and cleaned up using the EpiTect Bisulfite
Kit (Qiagen) according to manufacturer’s protocol. Bisulfite converted DNA (7.5% of
total per reaction) was then PCR amplified using KAPA HiFi Uracil+ Readymix (Roche)
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according to manufacturer’s protocol. PCR products were purified with Ampure XP
beads (Beckman Coulter), A-tailed with Amplitaq polymerase (Applied Biosystems),
ligated into pGEM Easy T vector (Promega) and transformed into NEB Turbo competent
cells (New England Biolabs) as described above. Amplicons were sequenced at the
University of Pennsylvania Sanger Sequencing core using the T7 promoter/primer.
Bisulfite analysis was carried out using BISMA software180 and only sequences with
>90% conversion rate were included in the analysis.

Genome Wide Methylation Analysis
Genome wide methylation analysis was carried out using the EPIC Array (Illumina, San
Diego, CA), which measures CpG methylation at ~800,000 sites. Samples were
transfected for 48hrs with either dCas9-DNMT3a-Puro, dCas9-DNMT3a-ANV-Puro or
Cas9-Puro + 190bp methylated template and gRNA targeting C9orf72. Samples were
puromycin selected for 48 hours and genomic DNA was extracted 4 days post
transfection. Samples were then bisulfite converted and processed using the Infinium
Methylation EPIC Kit (illumina) by the Center for Applied Genomics at Children’s
Hospital of Philadelphia. Data was analyzed in R using the Bioconductor package
ChAMP181. Data was normalized with the beta-mixture quantile normalization method
(BMIQ) and significantly differentially methylated probes were called using default
parameters with the Benjamini-Hochberg procedure for false discovery rate adjustment.

RNA Expression from iPSCs
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Cells were harvested via Accutase (Stem Cell Technologies), pelleted, washed in PBS
and resuspended in 350ul RLT buffer (Qiagen). Lysates were homogenized via pipetting
and vortexing and RNA was extracted using the RNeasy kit (Qiagen) with on-column
DNAse digest for 15 minutes at room temperature. 1μg of RNA was converted to cDNA
using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems)
according to manufacturer’s protocol. cDNA was diluted tenfold and 4μl was used in a
qPCR reaction with 2X FastStart Universial SYBR Green master mix (Roche) and
0.25μM of each primer. qPCR was run with default cycling conditions on a StepOne Plus
qPCR machine (Applied Biosystems). Relative expression was calculated using the delta
delta Ct method by normalizing to housekeeping genes (ACTB, GPS).

Chromatin Immunoprecipitation
Edited iPSC clonal lines were cross-linked with 1% formaldehyde (37⁰ C, 10 minutes)
and quenched with 125μM glycine. Cells were lysed (0.5% SDS, 10mM EDTA, 50mM
Tris/HCl, pH 8) and sonicated on high power for 30 cycles using a Bioruptor 300
(Diagenode, Denville, NJ). 1μg of chromatin was incubated overnight at 4⁰ C with
Protein A Dynabeads (Life Technologies) and 5μl of antibody against H3K9me3 (Cell
Signaling #13969) or IgG. Beads were washed with buffers of increasing stringency
(Low salt, high salt, lithium chloride and 1X TE buffer) and DNA was eluted in buffer
containing 1% SDS. RNA and protein were digested using RNAse A (Thermo Scientific)
and proteinase K (Promega). DNA was purified using PCR purification kit (Qiagen) and
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eluted in 200μl EB Buffer (Qiagen). 4μl purified DNA was inputted into a qPCR reaction
as described above and percentage of input was calculated for each sample.

Results
Targeted DNA methylation using oligonucleotide repair templates
As DNMTs are recruited to DNA damage sites, we tested the hypothesis that a
dsDNA break induced by Cas9 in an endogenous locus would result in increased DNA
methylation. HEK293T cells were transfected with a plasmid encoding for Cas9 with or
without a gRNA specific to the C9orf72 promoter, together with a negative control single
stranded oligonucleotide non-homologous DNA repair template. Methylation was
measured at a CpG site in the promoter region (Figure 2.1A) using a previously
developed methylation sensitive restriction enzyme digest qPCR assay (MSRE-qPCR)137.
This assay provides a quantitative measure of methylation of the C9orf72 promoter based
on resistance of DNA to digestion by the methylation-sensitive HhaI enzyme and the
primers used anneal outside the repair templates and thus can only amplify genomic
DNA. In the absence of gRNA, there were no measurable changes in methylation
(Figure 2.1B), regardless of the presence or absence of various exogenous
oligonucleotide repair templates. In contrast, cells transfected with plasmids encoding
Cas9, a gRNA targeting C9orf72 and the non-homologous repair template, exhibited an
increase in promoter methylation in unselected cells (Figure 2.1B). Endogenous dsDNA
breaks in this context are repaired mainly through non-homologous end joining
(NHEJ)164. Thus, a double strand break alone, in the absence of HDR, appears to induce
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methylation of the C9orf72 promoter. Methylation in this condition, however, was
transient and dissipated after only five days in culture (Figure 2.1F).
To test the hypothesis that DNA methylation can be copied from an exogenous
repair template into the genome, HEK293T cells were then transfected with Cas9, gRNA
targeted to the C9orf72 promoter and a single stranded oligonucleotide homologous
repair template that was either unmethylated or methylated at every CpG dinucleotide (10
sites total). Cells that received an unmethylated homologous template had a reduction in
methylation compared to those transfected with the non-homologous template, and cells
transfected with a methylated repair template showed increased methylation when
compared to those transfected with the unmethylated template (Figure 2.1B). These
results suggest that methylation of the exogenous repair template promotes methylation
of the endogenous C9orf72 promoter.
To measure NHEJ, a T7 endonuclease assay was used that digests mismatched
PCR amplicons180. As a readout of HDR, a 2bp mutation was made in the repair template
that creates an SspI restriction enzyme site (Figure 2.1A). NHEJ efficiency was similar
between conditions and was consistently higher than HDR rates as expected (Figure
2.1C-E), which perhaps underlies the observation that methylation in the nonhomologous template condition was the highest (as NHEJ is more frequent than HDR).
The methylation associated with the methylated oligonucleotide repair template was
slightly more stable, but still returned to baseline eight days post transfection (Figure
2.1G). Thus, NHEJ and HDR were associated with transient DNA methylation of the
C9orf72 promoter following Cas9-mediated DNA damage.
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To test the precision of HDR dependent methylation, we designed an
oligonucleotide repair template with a single methylated CpG site, corresponding to the
HhaI restriction enzyme site used in our methylation assay (Figure 2.1H). If methylation
of this single CpG site was copied via HDR, it should block HhaI digestion with similar
efficiency as the fully methylated template. Indeed, HEK293T cells transfected with
Cas9 and the single methylated CpG repair template had similar HhaI resistance as cells
transfected with Cas9 and the fully methylated template (Figure 2.1H). Thus, a single
stranded oligonucleotide template with a single methylated CpG site appears to be
sufficient to target methylation to the C9orf72 promoter in a transient manner.

Longer double stranded templates improve methylation efficiency and stability
While it appeared that methylation of the endogenous C9orf72 promoter could be
induced upon HDR with a methylated exogenous oligonucleotide repair template,
methylation appeared to be relatively inefficient and transient. To enhance DNA
methylation efficiency and stability, we tested the ability to introduce DNA methylation
via HDR using longer double stranded DNA (dsDNA) repair templates. In vitro
methylated dsDNA repair templates with 190bp (10 CpGs), 600bp (35 CpGs) and 1.4kb
(53 CpGs) total homology to the C9orf72 promoter were generated (Supplemental Table
3.S2) with mutations of the CRISPR PAM site to disallow repeat cutting of edited loci
and to monitor HDR efficiency (Figure 2.2A). Unmethylated versus fully methylated
repair templates were co-transfected with plasmids encoding CRISPR-Cas9 components
into HEK239T cells. After four days, methylation was tested using a long amplicon
MSRE-qPCR assay that only amplifies genomic DNA and not the repair templates.
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Indeed, longer dsDNA templates induced more CpG methylation in a length dependent
manner, with the longest repair template group showing more than two fold higher
methylation levels than the shortest template group (Figure 2.2B).
HDR efficiency was monitored using restriction digests of genomic DNA PCR
products to detect mutations of the PAM recognition site that is present in the DNA
repair templates. HDR efficiency of the different templates does not explain the observed
differences in DNA methylation, as the shortest 190bp methylated repair template
resulted in the most HDR but the least amount of DNA methylation (Figure 2.1B and
Supplemental Figure 2.1). Moreover, the methylation status of the repair template did not
appear to affect HDR efficiency (Supplemental Figure 2.2). Additionally, upon
comparing the 190bp dsDNA repair template versus the single stranded oligonucleotide
repair template, there was a non-significant increase in methylation associated with the
dsDNA template (Supplemental Figure 2.2), suggesting that DNA strandedness does not
account for the increase in methylation efficiency when using longer dsDNA repair
templates. Together, these results suggest that the length of the dsDNA repair template
was the main factor that allowed for more efficient induction of DNA methylation.
Next, the HARDEN method of targeted DNA methylation was compared to the
previously developed dead Cas9 (dCas9) DNMT3a catalytic domain fusion protein
construct152. HEK293T cells were transfected with either Cas9+gRNA to C9orf72 and
the 1.4kb dsDNA methylated repair template or the dCas9-DNMT3a construct with the
same gRNA. As negative controls, cells were transfected with catalytically inactive
DNMT-dCas9 fusion enzyme (dCas9-DNMT3a-ANV) or Cas9 plasmid without gRNA.
In control groups, there was very little detectable methylation using MSRE-qPCR (Figure
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2.2C). Robust levels of methylation were induced using either dCas9-DNMT3a or
HARDEN; however, the HARDEN method induced ~50% more methylation and thus
has slightly improved efficiency at this locus. Notably, the same gRNA was used for
both methods (Figure 2.2C). These results indicate that HARDEN may be an effective
alternative method for targeted DNA methylation of the C9orf72 locus.
Next, we tested whether methylation copied from a long dsDNA repair template is stably
maintained after cell division, as this is important for targeted methylation editing
applications. Cells were transfected with Cas9 and gRNA targeting C9orf72 and either
non-homologous repair template, unmethylated 1.4kb dsDNA repair template or
methylated 1.4kb dsDNA repair template. As a control, cells transfected with Cas9
plasmid without gRNA and with a non-homologous repair template were used.
Methylation was measured by MSRE-qPCR at the indicated days post transfection. Cells
that were transfected with methylated template maintained higher methylation levels than
controls and remained stable throughout the 30 day time course (Figure 2.2D).
Additionally, cells transfected with either the unmethylated or methylated 1.4kb repair
templates were sub-cloned and screened for clonal lines that underwent HDR using the
repair template via PCR and restriction enzyme digest (Figure 2.2E-F). Clones were
passaged from single cells and analyzed ~5 weeks after transfection of CRISPR
components and repair template. 9 out of 13 clones (69.2%) that were repaired with the
methylated template acquired >10% methylation, compared to only 1 clone out of 16
(6.3%) repaired with the unmethylated template (Supplemental Figure 2.3) as measured
by MSRE-qPCR. Furthermore, all three clones that were repaired with the methylated
template on both alleles became hypermethylated, with levels of methylation ranging
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from 60-80% by both MSRE-qPCR and bisulfite sequencing of cloned amplicons (Figure
2.2G-H). Thus, repair with methylated dsDNA repair templates promotes stable and
dense methylation of the C9orf72 promoter.

DNA Methylation is acquired via Homology Directed Repair
Next, the underlying mechanisms of HARDEN were explored to better
understand the efficiency and required proteins for this process. The first question tested
was what percentage of DNA molecules that are repaired with an exogenous methylated
repair template actually undergo copying of methylation into the endogenous DNA. To
address this question, a ~1200bp dsDNA repair template was designed to insert a 12bp
mutation that would serve as a primer site to specifically amplify genomic DNA in which
the mutation is incorporated via HDR (Figure 2.3A). HEK293T cells were transfected
with CRISPR components and either an unmethylated or methylated version of this
template. Bisulfite PCR of genomic DNA from transfected cells showed that the mutation
specific PCR only amplified DNA from cells that were co-transfected with repair
template (Figure 2.3B). Bisulfite sequencing of these cloned amplicons revealed that
DNA repaired with the unmethylated template was rarely methylated, with ~5% of total
CpGs methylated (Figure 2.3C-D) and only 1/27 amplicons having at least 20%
methylation (Figure 2.3E). In comparison, DNA repaired with the methylated template
was methylated at greater than 50% of CpGs throughout much of the amplicon(Figure
2.3C-D) and had 24/31 highly methylated amplicons (Figure 2.3E). Moreover, bisulfite
sequencing revealed that DNA methylation in the setting of HDR did not induce DNA
methylation of the last 3’ CpG site within the bisulfite amplicon (CpG site #22, Figure
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2.3C). This is notable because the repair template covered the entire bisulfite amplicon
except this 3’ CpG site, consistent with our hypothesis that DNA methylation is copied in
a templated manner. Thus, repair with a methylated homologous template facilitates
methylation of the endogenous locus.
Next, siRNA knockdowns of DNA methyltransferase enzymes were carried out to
determine which DNMTs are required for methylation during this process. siRNA against
either DNMT1, DNMT3a, DNMT3b, and the DNMT1 recruiting factor UHRF1 were
first transfected into HEK293T cells, and 24 hours later, the CRISPR components and a
methylated 1.4kb repair template were introduced. Methylation was measured by MSREqPCR following an additional 48 hour incubation period. Knockdown of any of these
proteins resulted in ~40-50% decrease in the amount of methylation acquired using
HARDEN (Supplemental Figure 2.4). These results indicate that there may be nonredundant roles for DNMTs and UHRF1 for the establishment and/or maintenance of
methylation during DNA repair.

Genome wide methylation of epigenetically edited cells
The previous results demonstrate that HARDEN can be a useful method for
targeted methylation of C9orf72. Next, the potential genome-wide off target effects of
HARDEN were explored and compared to the dCas9-DNMT3a catalytic domain fusion
protein construct. Because HARDEN utilizes both the 20bp gRNA sequence and a
homologous repair template to induce methylation, we hypothesized that HARDEN
would be highly specific for the targeted locus. To test this, HEK293T cells were
transfected with either the dCas9-DNMT3a construct, or CRISPR components and
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methylated repair template (C9orf72+ Meth). As negative controls, catalytically inactive
dCas9 enzyme (dCas9-DNMT3a-ANV) or Cas9 plasmid without gRNA but with a
methylated repair template (No gRNA+Meth) were used. Non-transfected cells were also
included as an additional control to ensure transfection did not perturb global DNA
methylation. Genome-wide methylation analysis was measured using genome wide
arrays that detect DNA methylation at ~800,000 CpG sites. No statistically significant off
target effects were detected using the HARDEN method (Figure 2.4A). This is in contrast
to the dCas9-DNMT3a fusion construct which resulted in massive off target methylation
(67,246 sites with p < 0.05) when compared to the dCas9-DNMT3a-ANV construct
(Figure 2.4B). These off-target effects are not attributable to the gRNA, as the same
gRNA was used for both the dCas9-DNMT3a group and the HARDEN group. When
looking at the raw methylation values across the genome, there was no difference in
methylation at lowly methylated sites between non-transfected cells or cells transfected
with HARDEN components (Figure 2.4C). However, cells transfected with dCas9DNMT3a showed a pronounced gain in methylation at lowly methylated sites compared
to non-transfected cells and cells transfected with dCas9-DNMT3a-ANV (Figure 2.4D).
These results suggest that HARDEN is a highly specific method for DNA methylation
editing and confirms previous findings that dCas9-DNMT3a fusion proteins have
massive global off-target effects.

Editing of Methylation in ALS patient derived iPSCs
ALS and FTD patients with the C9orf72 repeat expansion can exhibit promoter
hypermethylation, which is thought to contribute to transcriptional repression of the
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C9orf72 gene137. To model this aspect of ALS/FTD, HARDEN was applied to previously
characterized patient derived iPSCs81 harboring the repeat expansion but with limited
C9orf72 promoter methylation (Supplemental Figure 2.5). IPSCs were transfected with
CRISPR components and either unmethylated and or methylated 1.4kb dsDNA
templates. Clonal lines were isolated and tested for incorporation of the PAM mutation
via HDR using restriction enzyme digestion of PCR amplicons (Figure 2.5A).
Methylation of edited clones was measured using MSRE-qPCR. Targeted methylation of
iPSCs was slightly less efficient than in HEK293Ts, but stably methylated clones were
obtained with methylation levels of ~20-50% (Figure 2.5B). DNA methylation levels
were confirmed by bisulfite sequencing of cloned amplicons (Figure 2.5D). Additionally,
chromatin immunoprecipitation (ChIP) was performed on clonal iPSCs using an
antibody against the repressive histone mark H3K9 trimethylation (Figure 2.5C). iPSCs
that gained DNA methylation also gained H3K9 trimethylation, indicating a switch to a
repressive chromatin state, and this increase was specific for the C9orf72 locus (Figure
2.5C, Supplemental Figure 2.6). Finally, RNA was extracted from these edited iPSCs and
mRNA levels of the major C9orf72 isoforms were measured via RT-qPCR (Figure 2.5E).
Methylated iPSC clones had reduced mRNA levels by ~50%, with the largest effect seen
for variant 3 (Figure 2.5H), which has a transcription start site closest to the targeted CpG
island. These results indicate that hypermethylation of the C9orf72 promoter CpG island
does indeed cause a reduction of C9orf72 expression, confirming previous reports that
were based only on correlative analysis47,137. Thus, HARDEN can be used to generate a
disease model of aberrant methylation and allows for defining the direct effect of DNA
methylation on gene expression at this locus.
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Discussion
This study highlights a novel method for targeted DNA methylation and applies it
to generate a cellular disease model. In doing so, several new findings about the interplay
between DNA damage repair pathways and DNA methylation were explored. First, these
results suggest that a targeted double strand break can induce DNA methylation of an
endogenous locus. Previous studies have demonstrated that repair of dsDNA breaks in a
GFP-based reporter construct can lead to DNA methylation following repair by either
NHEJ172 or HDR167–170. This study demonstrates that this process also occurs at an
endogenous gene, although methylation acquired following NHEJ is not maintained
through cell division and is lost within 5 days in culture. The reduction in methylation
observed following NHEJ is consistent with passive demethylation, with ~50% reduction
each day. These results indicate that localized DNA methylation may serve as a transient
marker of dsDNA breaks, perhaps to prevent transcription and promote stability of
potentially mutagenized DNA.
Another finding is that methylation appears to be copied from either a single or
double stranded DNA template through the process of HDR, including from
oligonucleotides harboring a single methylated CpG site. This level of specificity could
be useful to study the effect of a particular CpG site on transcription factor binding.
Longer double stranded templates seem to be more efficient at inducing methylation than
short single stranded oligonucleotide templates and methylation induced via dsDNA
templates can be stably maintained over numerous cell divisions in both HEK293T cells
and iPSCs. Our results suggest that template length is more important than strandedness
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for inducing methylation, as there is only a small, non-significant increase in efficiency
between 190bp ssOligo templates and the corresponding 190bp dsDNA template. In
contrast, there are more sizeable observed differences in efficiency between 190bp,
600bp and 1.4kb dsDNA templates. It is not clear whether this effect is due to the overall
increase in the number of methylated CpGs or if the longer templates include key CpG
sites necessary for stable methylation of the C9orf72 promoter. There is evidence, for
example, that specific transcription factor binding sites may be more important than the
total number of methylated CpGs for determining promoter methylation state182.
Knockdown of DNA methyltransferase enzymes revealed that both de novo (DNMT3a
and 3b) and maintenance methyltransferases (DNMT1) as well as UHRF1 are required
for efficient methylation using HARDEN. These enzymes have previously been shown
to assemble at double strand DNA break sites160,168,169, and UHRF1 is thought to be
important for double strand break repair in addition to its role in maintenance
methylation183. Thus, it appears that an interplay of these enzymes and cofactors function
in concert to promote methylation during DNA damage repair, although they may
function in different repair sub-pathways .
HARDEN was also compared to the dCas9-DNMT3a fusion protein, and it
appears that HARDEN has slightly better on-target efficiency at C9orf72 than the dCas9DNMT3a construct. Importantly, HARDEN has no detectable off-target effects, whereas
the dCas9-DNMT3a fusion protein induces tens of thousands of off-target methylation
changes. While only the off-target effects of a single gRNA are compared here, other
studies have documented that dCas9-DNMT3a fusion proteins have large off-target
effects irrespective of the gRNA used153,154.
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HARDEN can also be used to make stably methylated cell lines that model epigenetic
alterations seen in ALS/FTD patients with the C9orf72 repeat expansion47,136,137. Indeed,
this study confirms for the first time that the endogenous C9orf72 promoter CpG island
directly regulates expression of this gene and that DNA methylation of this region leads
to an increase in histone H3K9 trimethylation. Interestingly, the overall levels of
methylation in clonal iPSCs are lower than in clonal HEK293Ts. This could be due to
differences in active demethylation between the cell types or selective pressure against
fully methylated C9orf72 in iPSCs. It is known that iPSCs require active demethylation
via TET enzymes to maintain pluripotency184.
We acknowledge that HARDEN may not the best targeted DNA methylation technique
for some applications. Since HARDEN appears to be linked to HDR, methylation
efficiency is dependent on HDR rates which can be low or absent in certain settings. For
instance, targeting post-mitotic cells or cell types that have a low frequency of HDR may
limit the utility of this method. Furthermore, since stable methylation editing requires
both a gRNA and repair template, multiplexing to target several genes at once would be
labor intensive. A final limitation is that in order to prevent cutting of the repair template,
a PAM mutation is required and thus scarless methylation editing without changing the
DNA sequence is difficult. Nevertheless, the cellular models established here using
HARDEN can be utilized to better understand the molecular consequences of C9orf72
hypermethylation in the context of the repeat expansion.

Figures
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Figure 2.1: Editing DNA methylation of C9orf72 using single stranded DNA templates
A) Diagram of C9orf72 gene structure. Red arrows indicate primers used for MSREqPCR. The forward primer anneals outside of the repair template. Green line indicates
HhaI site that is being tested for methylation in (B). B) MSRE-qPCR of a CpG site within
the C9orf72 promoter in HEK293T cells transfected with CRISPR/cas9 plasmid and the
indicated single stranded oligonucleotide repair templates. Cells were collected 2 days
post transfection. n =3 experiments. One way ANOVA followed by Bonferroni pairwise
comparisons. All groups with gRNA are significantly different than those without gRNA.
****p < 0.0001, ***p < 0.001, **p < 0.01. C) Representative PCR + Digest with T7
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endonuclease I from experiments shown in (B). Digest with T7 estimates the total amount
of mismatched DNA (Indels and copying of the 2bp PAM mutation via HDR). D)
Representative PCR + digest with SspI restriction enzyme from experiments shown in
(B). SspI digest estimates the rate of HDR (copying of the 2bp PAM mutation creates
SspI restriction enzyme site). n = 6 experiments. E) Quantification of T7 and SspI Digest
assays. n =6 experiments. 2 way ANOVA shows significant interaction between sample
group and digest assay (p = 0.0004). Bonferroni Post hoc tests were carried out between
groups within each assay. F) MSRE-qPCR timecourse of HEK293T cells transfected
with Cas9+gRNA and no repair template. n =3 experiments. G) MSRE-qPCR timecourse
of HEK293T cells transfected with Cas9 and ssoligo repair templates. n =3 experiments.
2 way ANOVA shows significant interaction between time post transfection and template
(p = 0.0010). Comparisons are made to Cas9 without gRNA transfected group. ****p <
0.0001, **p < 0.01, *p < 0.05. H) MSRE-qPCR of HEK293T cells transfected with
Cas9+gRNA and either a fully unmethylated template, a fully methylated template or a
template with a single methyl-CpG on the HhaI site. Cells were collected days post
transfection. n =6 experiments. One way ANOVA followed by Bonferroni pairwise
comparisons. **p < 0.01, *p < 0.05.
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Figure 2.2: Editing DNA methylation with double-stranded repair templates. A) Diagram
of double stranded DNA repair templates (either fully methylated or fully unmethylated
at CpG sites) homologous to the C9orf72 promoter. Red box indicates a 2 bp substitution
that generates a restriction enzyme site and mutates the PAM sequence. B) MSRE-qPCR
assay to measure DNA methylation using a long amplicon that anneals outside the repair
templates. HEK293T cells were transfected with CRISPR/Cas9+gRNA and the indicated
templates. Cells were puromycin selected for 2 days and collected at day 4 post
transfection. n =3 experiments; 2 way ANOVA shows significant interaction between
template length and template methylation status (p = 0.0071). Bonferroni post hoc test
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between unmeth and meth template groups ****p < 0.0001, *** p < 0.001. C)
Comparison of methylation efficiency between HARDEN method and dCas9-DNMT3a
fusion protein construct. HEK293T cells were transfected with indicated plasmids and
methylation was measured 2 days post transfection using long amplicon MSRE-qPCR. n
=3 experiments. One way ANOVA (p < 0.0001) followed by Bonferroni comparison of
indicated groups. ****p < 0.0001, **p < 0.01, *p < 0.05. D) Timecourse of methylation
measured via long amplicon MSRE-qPCR using 1.4kb dsDNA repair templates. n =3
experiments. 2 Way ANOVA (Group p < 0.0001; day post transfection p = 0.0343)
followed by Bonferroni comparison between unmethylated template and methylated
template groups. ** p < 0.01. E) Diagram of C9orf72 promoter region indicating the
position of the repair template used to generate stably methylated HEK293T clones. Red
box indicates a 2 bp substitution that generates a restriction enzyme site and mutates the
PAM sequence. F) PCR and digest of HEK293T clonal lines that were repaired using the
1.4kb dsDNA repair templates. Cells were collected ~5 weeks post transfection. G)
MSRE-qPCR of clonal cell lines that were homozygous for editing with either the
unmethylated (n =2) or methylated 1.4kb repair template (n =3). Cells were collected ~5
weeks post transfection. Two tailed t-test; p = 0.0020. H) Bisulfite amplicon sequencing
of homozygous clonal cell lines edited with the unmethylated or methylated 1.4kb repair
templates. Cells were collected ~5 weeks post transfection. Each row is an individual
DNA molecule and columns are individual CpG dinucleotides. Grey boxes indicate
unmethylated CpGs, black boxes indicate methylated CpGs and white boxes are
undetermined due to poor conversion or poor sequencing quality.
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Figure 2.3: DNA methylation is associated with Homology Directed Repair. A) Diagram
showing the targeted region of C9orf72. Purple arrows indicate primers that amplify wild
type DNA, whereas the red arrow indicates the primer that specifically amplifies a 12bp
mutation that was included in the repair template. B) Bisulfite PCR using the primers
depicted in (A). Representative gel from two biological replicates. C) Bisulfite amplicon
sequencing from two biological replicates (Unmeth: n= 27 amplicons, Meth: n =31
amplicons). Each row is an individual cloned and sequenced DNA molecule and columns
are individual CpG dinucleotides. Grey boxes indicate unmethylated CpGs, black boxes
indicate methylated CpGs and white boxes are undetermined due to poor conversion or
poor sequencing quality. D) Quantification of percent methylation at each CpG site
sequenced in (C). n =2 biological replicates and 22 CpG sites. E) Quantification of the
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number of amplicons with less than or greater than 20% methylation. Data are from 2
biological replicates. Fisher’s Exact Test, p < 0.0001.
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Figure 2.4: Genome-wide methylation analysis of HARDEN and Cas9-DNMT3a based
methods. A) Methylation values from HEK293T cells transfected with Cas9+gRNA to
C9orf72 and a methylated repair template vs those without gRNA. Methylation was
measured on an Illumina Epic Methylation Array with ~800,000 probes. Cells were
puromycin selected and collected at day 4 post transfection. n =3 biological replicates;
Colored dots indicate differentially methylated probes calculated using the Benjamini–
Hochberg procedure. Black = not significant (adjusted p > 0.05); Yellow = adjusted p <
0.05; Red = adjusted p < 0.01. B) Methylation values from HEK293T cells transfected
with either dCas9-DNMT3a or catalytically dead dCas9-DNMT3-ANV along with
gRNA to C9orf72. Cells were puromycin selected and collected at day 4 post
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transfection. n =3 biological replicates. Methylation was measured on an Illumina Epic
Methylation Array with ~800,000 probes. Colored dots indicate differentially methylated
probes calculated using the Benjamini–Hochberg procedure. Black = not significant
(adjusted p > 0.05); Yellow = adjusted p < 0.05; Red = adjusted p < 0.01. C) Raw
methylation values vs the density of probes genome-wide for non-transfected cells (n =2),
Cas9+gRNA and methylated template (n =3) or Cas9 without gRNA and methylated
template (n =3). Methylation was measured on an Illumina Epic Methylation Array with
~800,000 probes. D) Raw methylation values vs the density of probes genome-wide for
non-transfected cells (n =2), dCas9-DNMT3a+gRNA to C9orf72 (N=3) or catalytically
dead dCas9-DNMT3-ANV+gRNA to C9orf72 (n =3). Methylation was measured on an
Illumina Epic Methylation Array with ~800,000 probes.
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Figure 2.5: Editing of DNA methylation in ALS patient derived iPSCs. A) PCR and
digest of clonal ALS patient derived iPSCs that were repaired using 1.4kb double
stranded dsDNA repair templates. B) MSRE-qPCR to measure DNA methylation of
clonal iPSCs that were homozygous for editing with the repair template. Cells were
puromycin selected for 2 days, subcloned at day 7 and collected at ~6 weeks post
transfection. n =2 measurements per cell line and 3-4 cell lines per group. C) Correlation
between H3K9 trimethylation levels measured by ChIP-qPCR (n =2 experiments and 3
cell lines per group) and DNA methylation measured by MSRE-qPCR. Linear regression,
R2 = 0.9242; p = 0.0022. D) Bisulfite amplicon sequencing from unmethylated or
methylated clonal iPSCs (n= 3 cell lines per group). Each row is an individual cloned and
sequenced DNA molecule and columns are individual CpG dinucleotides. Grey boxes
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indicate unmethylated CpGs, black boxes indicate methylated CpGs and white boxes are
undetermined due to poor conversion or poor sequencing quality. E) Diagram of
C9orf72 gene structure. Black triangle indicates the Cas9 cut site, colored arrows indicate
transcription start site and black arrow indicates the protein coding start site. F) RT-qPCR
of all C9orf72 variants in methylated or unmethylated clonal iPSCs. n =3 cell lines per
group. Two-tailed t-test, p = 0.0021 G) RT-qPCR of C9orf72 variant 2 in methylated or
unmethylated clonal iPSCs. n = 3 cell lines per group. Two-tailed t-test, p = 0.0056. H)
RT-qPCR of C9orf72 variant 3 in methylated or unmethylated clonal iPSCs. n =3 cell
lines per group. Two-tailed T-test, p = 0.0048.
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Supplemental Figures and Tables

Supplemental Figure 2.1: Comparison of HDR efficiency in different length templates.
Quantification of PCR + SspI Digest in HEK293T cells transfected with the indicated
templates. Cells were puromycin selected for 2 days and collected at day 4 post
transfection. n = 3 experiments. 2 way ANOVA shows template size has significant
effect (p < 0.0001) whereas methylation status does not (p = 0.6110). Bonferroni post hoc
tests were carried out between unmeth and meth groups at each template length.
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Supplementary Figure 2.2: Comparison of ssDNA vs dsDNA templates. MSRE-qPCR
of HEK293T cells transfected with either 190bp ssOligo or 190bp dsDNA methylated
templates and the CRISPR/cas9 components. Cells were puromycin selected for 2 days
and collected at day 4 post transfection. n = 3 experiments. One Way ANOVA (p =
0.0126) followed by Bonferroni test.
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Supplementary Figure 2.3: MSRE-qPCR of HEK293T clonal lines repaired with either
an unmethylated or methylated repair template. Cells were analyzed for HDR and
methylation ~5 weeks post transfection. Shown here are clones that had at least 25%
HDR (measured via SspI digest). n = 16 unmeth clones, 13 meth clones. Two-Tailed TTest, p = 0.0004.
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Supplementary Figure 2.4: Effect of DNMT knockdown on targeted methylation of
C9orf72. siRNA was transfected 24 hours prior to transfection of CRISPR components
and 1.4kb methylated template into HEK293T cells. Cells were collected 4 days post
transfection. Methylation was measured via long amplicon MSRE-qPCR and normalized
to scrambled control. n = 3 experiments; 1 way ANOVA followed by Bonferroni post
hoc tests. *** p < 0.001; **** p < 0.0001.
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Supplementary Figure 2.5: Repeat Primed PCR of iPSCs derived from ALS patient
with C9orf72 repeat expansion. Capillary electrophoresis traces from fluorescently
labeled repeat primed PCR on unedited or edited clonal iPSC lines repaired with either
the 1.4kb unmethylated dsDNA template or methylated dsDNA template.
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Supplementary Figure 2.6: H3K9me3 chromatin immunoprecipitation followed by
qPCR of unmethylated and methylated clonal iPSCs. Off-target positive control is the
PAPC1 gene body, whereas the negative control is the PAPC1 promoter region. n = 3 cell
lines per group and 2 technical replicates. One way ANOVA (p = 0.0001) followed by
Bonferroni post hoc tests between indicated groups. **p < 0.01.
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Table 2.S1: Primers and gRNA sequences

Forward Primer Sequence (5’-3’)

Reverse Primer Sequence (5’-3’)

Assay

CAGTGTGAAAATCATGCTTGAGAGA

TTTGTGCTTGGTAGGCAGTG

TGCTCTTTGAGAAAATTCATTGG

TTTGTGCTTGGTAGGCAGTG

TGGCACTATTAAGGATCTGAGGAG

GGAGAGAGGGTGGGAAAAAC

DNA methylation
analysis q-PCR;
ChIP-qPCR
DNA methylation
analysis q-PCR
(long templates)
HDR analysis
PCR (long
templates)

TACCAGGGTTTGCAGTGGAG

GGAGAGAGGGTGGGAAAAAC

T7/HDR analysis
(oligo templates)

GGAGTTGTTTTTTATTAGGGTTTGTAGT

TAAACCCACACCTACTCTTACTAAA

Bisulfite Cloning
PCR

AGTTTTTTTTATTAAGGTTYGTATA

TTTCTTCTAATTAATCTTTATCAA

TTTAGTAGTTTTTGAATAATATTGG

TTTCTTCTAATTAATCTTTATCAA

CCCACTTCATAGAGTGTGTGTTG

TTCCATTCTCTCTGTGCCTTC

Bisulfite Cloning
Primer Insert - WT
Bisulfite Cloning
Primer Insert Mutant
Total C9orf72
mRNA (all
variants)

CGGTGGCGAGTGGATATCTC

TGGGCAAAGAGTCGACATCA

C9orf72 variant 2
mRNA

GCAAGAGCAGGTGTGGGTTT

TGGGCAAAGAGTCGACATCA

6FAM-AGTCGCTAGAGGCGAAAGC

TACGCATCCCAGTTTGAGACG

TACGCATCCCAGTTTGAGACGGGGGCCGGGGCCGGGGCCGGGG

CACCGTAGCGTGTGCGAACCTTAAT

AAACATTAAGGTTCGCACACGCTAC
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C9orf72 variant 3
mRNA
C9orf72 Repeat
Expansion
Detection
C9orf72 Repeat
Expansion
Detection
CRISPR gRNA
sequences (oligos
for cloning)

Table 2.S2: Repair template sequences with PAM mutation highlighted

Name

Sequence

Length (bp)

Nonhomologous
template

CAGAAGAAGAAGGGCTCCCATCACATCAACCGGTGGCGCATTGCCACGAAGCAGGCCAATGGGGAGGACATCGATGTCACCTC
CAATGACAAGTTGCT
AGCGGTGGGCAACCACAAACCCACGAGGGCAGAGTGCTGCTTGCTGCTGGCCAGGCCCCTGCGTGGGCCCAAGCTGGACTCT
GGCCACTCCCT

191

190bp ssOligo
template

CTAGCGAAATGGGGCGGGGCAACTTGTCCTGTTCTTTTATCTTAAGACCCGCTCTGGAGGAGCGTTGGCGCAATAGCGTGTGCG
AAC
CTTAATATTGGAGGCTGCTGGATCTGGAGAAAGTGAAGACGATTTCGTGGTTTTGAATGGTTTTGTTTGTGCTTGGTAGGCAGTG
GGCGCTCAACACATAATT

190

600bp dsDNA
template

AGGCACCGCAACCGCAGCCCCGCCCCGGCCCCTAGCGCGCGACTCCTGAGTTCCAGAGCTTGCTACAGGCTGCGGTTGTTTCCCTCCTTGTTTTCTTCTGGTTAATCTTTATCAGGTCTTTTCTTGTTCACCCTCAGCGAGTACTGTGAGAGCAAGTAGTGGGGAGAGAGGGTGGGAAAAACAAAAACACACACC
TCCTA
AACCCACACCTGCTCTTGCTAGACCCCGCCCCCAAAAGAGAAGCAACCGGGCAGCAGGGACGGCTGACACACCAAGCGTCATCTTTTACGTGGGCGGAACTTGTCGCTGTTTGACGCACCTCTCTTTCCTAGCGGGACACCGTAGGTTACGTCTGTCTGTTTTCTATGTGCGATGACGTTTTCTCACGAGGCTAGCGAAATGGGGCGGG

TTAATATTGGAGGCTGCTGGATCCGGAGAAAGTGAAGACGATTTCGTGGTTTTGAATGGTTTTGTTTGTGCTTGGTAGGCAGTGGGCGCTCAACAAATAATTGGTGGATGAAATTTTGTTTTTACC
GTAAGA CACTGTTAAG

GCAACTTGTCCTGTTCTTTTATCTTAAGACACGCTCTGGATGAGCGTTGGCGCAATAGCGTGTGCGAACC

621

CCCCGCCCCGGGCCCGCCCCCGGGCCCGCCCCGACCACGCCCCGGCCCCGGCCCCGGCCCCTAGCGCGCGACTCCTGAGTTCCAGAGCTTGCTACAGGCTGCGGTTGTTTCCCTCCTTGTTTTCTTCTGGTTAATCTTTATCAGGTCTTTTCTTGTTCACCCTCAGCGAGTACTGTGAGAGCAAGTAGTGGGG

1.4kb dsDNA
template

AGAGAGGGTGGGAAAAACAAAAACACACACCT
CCTAAACCCACACCTGCTCTTGCTAGACCCCGCCCCCAAAAGAGAAGCAACCGGGCAGCAGGGACGGCTGACACACCAAGCGTCATCTTTTACGTGGGCGGAACTTGTCGCTGTTTGACGCACCTCTCTTTCCTAGCGGGACACCGTAGGTTACGTCTGTCTGTTTTCTATGTGCGATGACGTTTTCTCACGAGGCTAGCGAAATGGGGC
GGGGCAACTTGTCCTGTTCTTTTATCTTAAGACCCG
CTCTGGAGGAGCGTTGGCGCAATAGCGTGTGCGAACC

TTAATATTGGAG

GCTGCTGGATCTGGAGAAAGTGAAGACGATTTCGTGGTTTTGAATGGTTTTGTTTGTGCTTGGTAGGCAGTGGGCGCTCAACACATAATTGGTGGATGAAATTTTGTTTTTACCGTAAGACACTGTTAAGTGCATTCAAAACTCCAC
TGCAAACCCTGGTAGGGGACAGCTCCGGC
ACTGCGGGCGGGAATCCCACGGTCCCCTGCAAAGTCATCGCAATTTTGCCTTTACATGTAAGAATTCTCTCAAGCATGATTTTCACACTGGGGAATGTCATTTTTGCTAGTTGCAATATGTGGATGAGTTGTTTTTTTTTAACTTTTGAAAAACGTACCATTCTGTTTGATGTGTAAAAAACACAAAGATTTTTGAAACCTTGCGTCTTTTGGTCTG
CAGGTGTATAGATTCCACTTACTACAGA
TGAGTAGCATTTACACCACTCAGATGTGTAAAAAAACAAAGGTTTTTTAAACTGTGTGCCTTTTGATCTGCAAGTGTGAGATGGCACTTACTACAGTGAGTAGCATTTAATCTTTTTCATCACTAAAAATCACACAGAACGTTTTAATCATTCACCGAGGAAGAAAGGGAGGAATAAATACACAAAATGGCTCTCAACGTCTACACCTTCTGCAGA
AACAGACCCTTTTCCTACTGTTCTATG
CTTTGTGAAAGTTGATCATACAAATTGGGTCATTCTTTTTATACCCAACTAAAATAGTGGGGGTAGGGGGTAGAAAAGCACTTAGGACAAATGACACTGCTCCCACAGTGTAATTCTCTCCAAGTCCAGCTGCTGCAACTGCCCGTTGTGACCTGAGACCAGTTTTATCTAATAGTTGCTAAAATGACCTGCTGCAGCTCTAATTTTATCTACCA

1415

CTCACCAGTT

CCATCA

AACTGGTGAGTGATGGTGGTAGATAAAATTAGAGCTGCAGCAGGTCATTTTAGCAACTATTAGATAAAACTGGTCTCAGGTCACAACGGGCAGTTGCAGCAGCTGGACTTGGAGAGAATTACACTGTGGGAGCAGTGTCATTTGTCCTAAGTGCTTTTCTACCCCCTACCCCCACTATTTTAGTTGGGTATAAAAAGA

PCR-insert
template

ATGACCCAATTTGTATGATCAACTTTCACAAA
GCATAGAACAGTAGGAAAAGGGTCTGTTTCTGCAGAAGGTGTAGACGTTGAGAGCCATTTTGTGTATTTATTCCTCCCTTTCTTCCTCGGTGAATGATTAAAACGTTCTGTGTGATTTTTAGTGATGAAAAAGATTAAATGCTACTCACTGTAGTAAGTGCCATCTCACACTTGCAG
ATCAAAAGGCACACAGTTTAAAAAACCTTTGTTTTTTTACACATCTGAGTGGTGTAAATGCTACTCATCTGTAGTAAGTGGAATCTATACACCTGCAGACCAAAAGACGCAAGGTTTCAAAAATCTTTGTGTTTTTTACACATCAAACAGAATGGTACGTTTTTCAAAAGTTAAAAAAAAACAACTCATCCACATATTGCAACTAGCAAAAATGACA
TTCCCCAGTGT
GAAAATCATGCTTGAGAGAATTCTTACATGTAAAGGCAAAATTGCGATGACTTTGCAGGGGACCGTGGGATTCCCGCCCGCAGTGCCGGAGCTGTCCCCTACCAGGGTTTGCAGTGGAGTTTTGAATGCACTTAACAGTGTCTTACGGTAAAAACAAAATTTCATCCACCAATTATGTGTTGAGCGCCCACTGCCTACCAAGCACAA
ACAAAACCATTCAAAACCACGAAATCGTCTTCACTTTCTCCAGATCCAGCAGCCTCC

GAATAATATTGGCCTATTAAGGTTCGCACACGCTATTGCGCCAACGCTCCTCCAGAGCGGGTCTTAAGATAAAAGAACAGGACAAGTTGCCCCGCCCCATTTCGCTAGCCTCGTGAGAAAACGTCATCGCACATAGAA

1248

AACAGACAGACGTAACCTAC

CACAGTA

GGTGTCCCGCTAGGAAAGAGAGGTGCGTCAAACAGCGACAAGTTCCGCCCACGTAAAAGATGACGCTTGGTGTGTCAGCCGTCCCTGCTGCCCGGTTGCTTCTCTTTTGGGGGCGGGGTCTAGCAAGAGCAGGTGTGGGTTTAGGAGGTGTGTGTTTTTGTTTTTCCCACCCTCTCTCCCCACTACTTGCTCT

CTC
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Abstract
Microsatellite repeat expansion disease loci can exhibit pleiotropic clinical and
biological effects depending on repeat length. Large expansions in C9orf72 (100s-1000s
of units) are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and
frontotemporal degeneration (FTD). However, whether intermediate expansions also
contribute to neurodegenerative disease is not well understood. Several studies have
identified intermediate repeats in Parkinson’s disease patients, but the association was not
found in autopsy confirmed cases. We hypothesized that intermediate C9orf72 repeats are
a genetic risk factor for corticobasal degeneration (CBD), a neurodegenerative disease
that can be clinically similar to Parkinson’s but has distinct tau protein pathology.
Indeed, intermediate C9orf72 repeats were significantly enriched in autopsy-proven CBD
(n=354 cases, odds ratio=3.59, p-value=0.00024). While large C9orf72 repeat
expansions are known to decrease C9orf72 expression, intermediate C9orf72 repeats
result in increased C9orf72 expression in human brain tissue and CRISPR/cas9 knockin
iPSC derived neural progenitor cells. In contrast to cases of FTD/ALS with large C9orf72
expansions, CBD with intermediate C9orf72 repeats was not associated with pathologic
RNA foci or dipeptide repeat protein aggregates. Knock-in cells with intermediate
repeats exhibit numerous changes in gene expression pathways relating to vesicle
trafficking and autophagy. Additionally, overexpression of C9orf72 without the repeat
expansion leads to defects in autophagy under nutrient starvation conditions. These
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results raise the possibility that therapeutic strategies to reduce C9orf72 expression may
be beneficial for the treatment of CBD.

Introduction
Large hexanucleotide repeat expansions (G4C2) in C9orf72 are the most common
genetic cause of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and
frontotemporal degeneration (FTD)43,44,116. ALS/FTD is characterized
neuropathologically by the presence of TDP-43 inclusions which are tightly linked to
neurodegeneration34. While the pathophysiologic mechanisms that lead to TDP-43
aggregation and neurodegeneration in the setting of large C9orf72 repeat expansions are
still unclear, both a loss of normal C9orf72 function and a toxic gain of function
attributed to repetitive RNA and protein aggregates have been proposed43,44,81,88,115. At
the protein level, C9orf72 regulates several vesicle trafficking pathways 56,67,70 and is
necessary for proper myeloid cell function in mice, but knockout of the protein does not
cause neurodegeneration58,59. On the other hand, the presence of the repeat expansion is
sufficient to induce neurodegeneration in several mouse models84,109. There is also
uncertainty in the repeat size threshold necessary to cause disease. Repeat expansions that
cause ALS/FTD are typically hundreds to thousands of units long and can differ
substantially between tissues45,185, making it difficult to accurately determine the
pathogenic repeat size threshold. There have been reports of pathogenic repeats as small
as 55-100 units in patient blood117,118. In contrast, non-diseased individuals typically
harbor repeats of 2-8 units186. Several studies have explored whether intermediate
C9orf72 expansions (e.g. those larger than controls but not large enough to cause
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ALS/FTD) are associated with risk for other neurodegenerative diseases, and these have
often yielded conflicting results119,124,125,186–191. For instance, a significant association
between intermediate expansion carriers and Parkinson’s Disease (PD) was reported in
clinically diagnosed PD125 and confirmed in a large meta-analysis123, but these
associations were not found in an autopsy confirmed PD cohort126. Other studies with
very small numbers of cases have also suggested that intermediate C9orf72 repeats are
associated with atypical Parkinsonian syndromes192,193. Thus, there is some evidence that
intermediate expansions in C9orf72 may confer risk for neurodegenerative diseases other
than ALS/FTD, but more exploration is needed to better understand the molecular
pathways and exact neurodegenerative diseases that are affected.
Here, we sought to determine whether intermediate expansions in C9orf72 are a
risk factor for corticobasal degeneration (CBD), a rare neurodegenerative disease that
shares some similar clinical features with PD such as limb rigidity, bradykinesia, tremor
and apraxia194. Patients that present with these neurologic features are often diagnosed
with corticobasal syndrome (CBS) because these symptoms can also be caused by several
other neurodegenerative diseases; definitive diagnosis of CBD requires neuropathology
autopsy examination195. CBD is characterized by hyper-phosphorylated tau aggregates in
neurons and astrocytes that are morphologically distinct from those found in Alzheimer’s
disease and other tauopathies196. Only ~25-50% of patients diagnosed with CBS are
confirmed as CBD at autopsy197–199, making clinically defined cohorts difficult to use for
genetic studies of CBD due to underlying neuropathological heterogeneity. In this study,
we determine whether C9orf72 intermediate expansions may be a risk factor for CBD by
measuring repeat size in the largest cohort of autopsy confirmed cases ever tested. In
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addition, we use post mortem CBD brain tissue to confirm the genetic findings, use
CRISPR/cas9 to modify the repeat number in human iPS cells at the endogenous locus,
and determine the effects of C9orf72 expression on autophagy. In doing so, we identify a
novel mechanism for how intermediate repeat expansions may affect CBD pathogenesis
that is distinct from large expansions that cause ALS/FTD.

Materials and Methods
Case Samples
Genomic DNA for repeat expansion size screening was obtained from 354 autopsy
confirmed CBD cases from 17 institutions. Institutions contributing the vast majority of
cases included Mayo Clinc, University College London and the University of
Pennsylvania. CBD patient cerebellum tissue for RNA expression studies was obtained
from the Center for Neurodegenerative Disease Research brain bank at the University of
Pennsylvania and from the Mayo Clinic brain bank. Brain autopsy material is not
considered human subjects research. However, legal consent for autopsy was obtained in
all instances. As a control cohort, we utilized a previously published global cohort of
healthy controls for which C9orf72 repeat sizing was available123.

Assessment of Repeat Expansion Size and SNP Genotyping
The CBD cohort was screened for intermediate C9orf72 repeat expansions using
fluorescent labeled touchdown PCR followed by fragment-length analysis on an ABI
3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA). PCR used 50ng
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genomic DNA in a final volume of 20ul containing 0.5U of Amplitaq Gold (Applied
Biosystems) and a final concentration of 1x Amplitaq Buffer I, 5uM reverse primer, 5uM
6FAM-fluorescent labeled forward primer, 1M Betaine, 5% DMSO, 0.25mM 7-deazadGTP, and 0.25mM of each dNTP. For detection of full expansions using repeat-primed
PCR, the Roche FastStart (Roche, Basel, Switzerland) polymerase system was used to
amplify 1ug of genomic DNA in a reaction with 0.9 mM MgCl2, 200nM dNTP mix,
180nM 7-deaza-dGTP, 1.4uM flanking primers, 0.175uM repeat primer, 7% DMSO,
.93M Betaine and 0.125 U polymerase. For both intermediate and full expansion
detection, a touchdown PCR cycling program was used where the annealing temperature
was gradually lowered from 70°C to 56°C in 2°C increments with a 3-minute elongation
time at 72°C for each cycle. SNP genotyping was carried out using Taqman probes as
previously described43. All primer sequences are listed in Supplemental Table 3.1.

Detection of RNA foci
RNA foci detection was performed on paraffin embedded cerebellum sections as follows:
Slides were deparaffinized with Xylene, followed by Xylene/Ethanol (1:1) and then
rehydrated with an ethanol series (100%, 90%, 80%,70% for 3 mins each). Slides were
incubated for 5 minutes in water, then digested with proteinase K (20ug/mL) for 10
minutes at 37 degrees in a buffer containing 10mM Tris-HCL pH 8 and 0.5% SDS in
DEPC-treated water. Slides were then washed twice with water then dehydrated with
increasing ethanol series and allowed to air dry. Slides were then prehybridized for 1
hour at 66 degrees in hybridization buffer containing 50% Foramide, 2X SSC, 50mM
NaHPO4 , and 10% Dextran sulfate in DEPC-treated water. Slides were hybridized with
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40nM probe (LNA 5TYE563C4G2; Exiqon (Denmark) # 300500, batch # 621440) at 66
degrees overnight. Slides were then washed once with 2X SSC + 0.1% Tween for 5 mins
at room temperature, then 3 times with 0.1X SSC for 10 minutes at 65 degrees. Slides
were then rinsed with water, stained with DAPI and mounted with coverslips using
Prolong glass antifade mountant (Invitrogen, Carlsbad, CA). Cases for RNA foci
detection included 12 non-expanded CBD, 9 intermediate CBD, 4 non-expanded control
cases (negative control) and 5 full expansion FTD/ALS cases (positive control).

Detection of Dipeptide Repeat proteins and Measurement of DNA methylation
Paraffin embedded cerebellum sections were deparaffinized and stained with antibodies
against p62, GA (1:7500), GP (1:7500) or GR (1:100) as previously described200. 116
non-expanded CBD, 9 intermediate CBD, 4 non-expanded control cases (negative
control) and 5 full expansion FTD/ALS cases (positive control) were stained. For
measurement of DNA methylation in CBD patient genomic DNA, 100ng DNA was
digested using the restriction enzymes HhaI and HaeIII (New England Biolabs, Ipswich,
MA) followed by qPCR as previously described137.

RNA Expression Analysis from Postmortem Brain and repeat edited NPCs
RNA was extracted from approximately 100mg of cerebellum tissue using Trizol reagent
(Life Technologies, Carlsbad, CA). RNA integrity was tested on an Agilent 2100
bioanalyzer using the RNA Nanochip 6000 kit (Agilent, Santa Clara, CA). Only RNA
samples with RIN values > 6 were included in this study. For repeat edited NPCs, cells
were pelleted at day 12 post induction and RNA was extracted using the RNeasy Kit
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(Qiagen). cDNA was prepared using random hexamers and Superscript III (Invitrogen)
according to manufacturer’s protocol. RT-qPCR was performed using SYBR Green
reagents (Roche) on a StepOne Plus Real-Time PCR Machine (Life Technologies). RNA
levels were normalized to the geometric mean of two housekeeping genes (ACTB, GPS1)
using the ∆∆Ct method. All primer sequences are listed in Supplemental Table 3.1.

CRISPR Editing of Repeat Size
CRISPR gRNAs were designed using the MIT CRISPR design tool
(http://crispr.mit.edu/) and cloned into the Cas9-GFP PX458 vector (Addgene,
Cambridge, MA) as previously described201. Repair templates were generated via PCR
cloning using genomic DNA from intermediate repeat carriers. PCR was carried out
using the FastStart Polymerase (Roche) with additives for GC rich templates (360nM 7deaza-dGTP, 7% DMSO, 930mM Betaine). PCR products containing 2 or 28 repeats
were cloned into pGEM Easy-T vector (Promega, Madison, WI) and verified by
sequencing. A 2 bp substitution was made at the PAM site in the repair template using
QuickChange site directed mutagenesis (Aligent) in order to prevent Cas9 cutting of the
repair template and to incorporate a restriction enzyme site (See Supplemental Figure
3.3). PX458 and repair template vectors were co-transfected into WT iPSCs202 using
Viafect reagent (Promega). On day 2 post transfection, GFP+ cells were sorted via FACS
(BD FACS Aria II) to 96 well plates for clonal isolation. DNA was extracted from 24
well plates of confluent clones using 0.2% SDS lysis buffer followed by phenolchloroform extraction. DNA from clones was PCR amplified and screened for homology
directed repair by restriction enzyme digest. Repeat size was measured as outlined above
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on positive clones, and all CRISPR edited cell lines were Sanger sequenced via PCR
cloning (10 clones/cell line).

Differentiation of iPSCs to Neural Progenitor Cells
IPSCs were differentiated via dual SMAD inhibition as previously described203. Single
cells were plated at high density (2x105/cm2) in mTeSR1 (StemCell Technologies,
Vancouver, Canada) + 10uM ROCK inhibitor Y27632 (ATCC) on Matrigel (Corning,
Corning, NY) coated 6 well plates. The following day, media was changed to neural
induction media (see Shi et al.203 for complete formulation) containing 10uM SB431542
(Tocris, Bristol, United Kingdom) and 1uM dorsomorphin (Sigma, St. Louis, MO).
Neural induction media was changed each day. At day 6, cells were split 1:2 into neural
induction media + ROCK inhibitor and media changes were continued until day 12. Day
12 NPCs were characterized for expression of NPC markers by immunofluorescence and
RT-qPCR. For western blot analysis, NPCs were passaged again at day 12 and collected
at day 16 post induction.

Western Blots and Antibodies
For detection of C9orf72, day 16 NPCs were pelleted, lysed (50mM Tris-HCl, 750mM
NaCl, 5mM EDTA, 2% SDS) and sonicated using a probe sonicator (Sonics Vibra-cell),
then spun at 21,000 g for 30 mins. BCA analysis (Pierce, Thermo Fisher) was performed
on cleared lysate to quantify protein expression. 50ug of protein was run on an 8% TrisGlycine gel, transferred using the Transblot Turbo system (Biorad, Hercules, CA) to a
nitrocellulose membrane and blocked for 1 hour at room temperature with Odyssey Licor
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Blocking buffer (Licor, Lincoln, NE). Membranes were blotted with the following
antibodies overnight at 4 degrees: anti-C9orf72 1:1000 (Millipore, Burlington, MA,
ABN1645), anti-GAPDH 1:1000 (Cell signaling Technology, Danvers, MA 2118S). IR
dye secondary antibodies (Licor) were used to detect protein on a Licor Odyssey. Protein
was quantified using Image Studio software (Licor).
For C9orf72 expression and autophagy experiments, cell lysates were prepared
in ice-cold radio immunoprecipitation assay (RIPA) buffer containing 150 mM
NaCl, 1% TritonX-100, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM Tris
(pH8.0) supplemented with protease and phosphatase inhibitors (PhosphoSTOP,
Roche). Cells were lysed for 20 min and centrifuged for 10 min at 13,500 rpm.
Protein concentration of the soluble fractions were determined using BCA reagent
(Thermo Fisher Scientific). 20-70ug of total protein was resolved using 10% or 12%
denaturing polyacrylamide gel electrophoresis and transferred to PVDF membrane
(Immobilon-P, PVDF). Proteins on PVDF membranes were blocked using 5% low-fat
milk in TBST containing 0.1% Tween-20 and incubated with primary antibody in
SuperBlock (TBS, Thermo Fisher Scientific) overnight at 4°C. The primary antibodies
used were: LC3 (ProteinTech, 14600-1-AP, 1:1000), and GAPDH (ProteinTech, 600041-Ig, 1:5000). The membranes were washed in TBST. Anti-rabbit or anti-mouse horseradish peroxidase (HRP) conjugated secondary antibodies (1:3000, Thermo Fisher
Scientific) in 5% milk in TBST were incubated with the membranes for 1 hour at room
temperature. The membranes were incubated with WestPico or WestFemto
chemiluminescent substrate (Thermo Fisher Scientific) and exposed to Amersham
Hyperfilm ECL films (GE Healthcare Life Sciences). The films were developed using
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Konica Minolta film developer. Protein band intensity was quantified using LI-COR
Image Studio Lite.

RNA sequencing in knockin intermediate repeat cells
50 base pair paired end RNA sequencing was carried out on day 12 post induction
isogenic NPC lines (See Supplemental Table 3.2) with 3 biological replicates per group
and 2 technical replicates per cell line. Libraries were prepared using the TrueSeq
Stranded mRNA and Ribo-zero rRNA removal kits (illumina, San Diego, CA).
Sequencing was carried out on a Hiseq 2500 (illumina) and at least 100 million reads
were generated per biological replicate. Adapter sequences were removed using
Cutadapt204. Reads were aligned to the genome (GRCh38) using STAR (v2.6) 205 with the
default mapping parameters and the read counts per gene were counted using the
quantMode function and genecode v29 annotation. Differentially expressed genes
between the short repeat group and intermediate repeat group were called using the
DEseq2 program (v1.22)206 with default parameters. Over enrichment analysis of
biological pathways was carried out using WebGestalt (2019) on genes that were either
upregulated or downregulated (adjusted p-value < 0.05) in the intermediate repeat group.
For comparison of genes dysregulated in full expansion carriers, differentially expressed
gene lists (adjusted p < 0.05 and >2 fold change) from two studies81,83 that compared
gene expression in iPSC derived neurons with full expansions vs. low repeat controls
were compared against the differentially expressed genes in this study (intermediate
repeat vs low repeat).
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Generation of stable C9orf72 expressing cell lines, transfection and drug treatments
The generation of an inducible single-copy C9orf72 transgene using Flp-In TRex-HeLa
cells was as described previously207. All cell lines used in this study were
maintained in DMEM (GE Healthcare HyClone, SH30243.01) with 10% FBS (GE
Healthcare HyClone, SV30160.03) and 1% Pen-Strep (Thermo Fisher Scientific,
15070063) at 37°C and 5% CO2. Tetracycline (Sigma-Aldrich, T7660) was added
(100 ug/ml) for 18 h to induce the expression of C9orf72 transgene. Parental HeLa
cells treated with tetracycline were used as controls in the experiments shown in Figure
3.6b and 3.7b. All plasmid transfections in cell lines were performed using Lipofectamine
2000 (Thermo Fisher Scientific, 11668019) or TurboFect (Thermo Fisher Scientific,
R0531) as per the manufacturer’s instruction. For autophagy experiments, Chloroquine
(CQ, Sigma-Aldrich) was dissolved in water (20 mM) and used at 40μM in the
media. Autophagy induction using Earle’s Balanced Salt Solution (EBSS, Gibco) was
incubated on cells following two successive PBS rinses. Incubation time for each
condition is stated in the respective figure legends.

Results
Screening of CBD patient DNA for C9orf72 expansions
To test the hypothesis that intermediate size expansions in C9orf72 are a risk factor for
CBD, genomic DNA from 354 autopsy confirmed CBD cases was screened using a PCRbased sizing assay (Figure 3.1a). We compared CBD patients to controls from a
previously published global meta-analysis of C9orf72 repeat size 123. We found that
1.84% of alleles from CBD cases (corresponding to 3.7%, or 13 cases) harbored
74

intermediate length repeat expansions compared to 0.52% of controls (Figure 3.1b-c, OR
= 3.59, p = 0.00024). This analysis was based on a minimum size cutoff of 17 which was
determined a priori and based on prior independent studies123,208. The increase in C9orf72
intermediate repeat allele frequency was not due to an increase in the frequency of the
C9orf72 repeat expansion haplotype between CBD patients verses non-diseased controls
or general global populations (Supplemental Table 3.3), and we did not detect any
expansions larger than 29 repeats (Supplemental Table 3.4). We conducted a post-hoc
analysis on our CBD cohort for each repeat length cut off below 18 repeats which
revealed that repeats as low as 10 units were associated with CBD (p = 0.026, OR =
1.36), where 61 out of 354 CBD cases had C9orf72 repeat alleles that were at least 10
units. This included 5 cases which had two alleles at 10 or greater. Although this posthoc analysis is considered exploratory209, there appeared to be a somewhat graded
increase in CBD risk with increasing repeat size (Figure 3.1d, Supplemental Table 3.5).
Overall these results indicate that intermediate expansions in C9orf72 may be a genetic
risk factor for CBD, and the risk may be additive with higher repeat sizes conferring
increased CBD risk.

C9orf72 expression from intermediate expansion carriers
Next, we determined how intermediate repeat expansions affect expression of the
C9orf72 gene. Previous studies have shown that large expansions in C9orf72, which
cause ALS/FTD, reduces mRNA from the expanded allele43,54,210. This reduction in
expression is often associated with hypermethylation of the C9orf72 promoter
region47,136,137,140. To test whether intermediate expansions alter C9orf72 DNA
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methylation and mRNA levels, we analyzed post mortem cerebellum samples from a
subset of 47 CBD cases for which frozen tissue was readily available. We measured
repeat expansion size, DNA methylation and C9orf72 mRNA levels of the two major
isoforms62 (Figure 3.2a, V2 and V3 isoforms). In this subgroup analysis, we again
observed high frequencies of intermediate repeat expansions between 17 and 29 units
(Supplemental Figure 3.1). Intermediate size expansions did not correlate with
hypermethylation of the promoter region, as is observed in full expansion cases
(Supplemental Figure 3.2). Surprisingly, total C9orf72 mRNA levels were positively
correlated with total C9orf72 repeat size (Figure 3.2b left, R2 = 0.276, p = 0.0034).This
positive correlation was not observed for the major isoform, V2, which has a
transcription start site downstream from the repeat expansion (Figure 3.2c left, R2 =
0.00496, p = 0.717). In contrast, V3 has a transcription start site upstream from the repeat
expansion and shows a robust positive correlation between repeat expansion size and
mRNA levels (Figure 3.2d left, R2 = 0.667, p < 0.0001). Cases with >17 total repeats
exhibited ~2.5 to 5 fold increase in variant 3 mRNA compared to cases with shorter
repeats. Finally, analysis of the variant 3 to variant 2 ratio also reveals a striking positive
correlation with larger repeat sizes (Figure 3.2e left, R2 = 0.849, p < 0.0001). Similar
results were obtained when using the largest repeat allele as opposed to the total C9orf72
repeat length (Figure 3.2b-e, right). However, total repeat number produced a stronger
positive correlation to C9orf72 mRNA levels, supporting an additive effect of repeat size
on expression.
To confirm the positive relationship between C9orf72 repeat size and mRNA
expression, we analyzed publicly available SNP eQTL data from the Genotype-Tissue
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Expression (GTEx) Project211. Large C9orf72 repeat expansion mutations invariably
occur within a 140kb haplotype block with a defined series of SNPs116,212. The SNP
rs3849942 is a commonly used marker for this haplotype block in which the G allele is
associated with small non-expanded C9orf72 alleles, and the A allele is associated with
both larger intermediate to full repeat expansions43. We observe the same trend in our
CBD genomic DNA cohort where the rs3849942 A risk allele was associated with larger
C9orf72 repeat sizes (Figure 3.2f). Using rs3849942 as a marker for longer/intermediate
repeats (as full expansions are rare in unselected populations), we used GTEx data to
determine if this SNP is associated with altered C9orf72 expression. We found that the
risk allele is significantly associated with increased C9orf72 expression across numerous
tissue types, with the largest effect size occurring in neural tissues (Figure 3.2g).
Expanding the analysis to 20 haplotype defining SNPs212, we found that 12 of the SNPs
on the risk allele are associated with increased C9orf72 expression in both the cortex and
basal ganglia (Figure 3.2h ). In contrast, there were no significant eQTL SNPs that led to
a decrease in expression. These results provide additional evidence that intermediate
expansions lead to increased C9orf72 expression.

CRISPR Editing of C9orf72 expansion size in iPSCs
In order to confirm the previous findings experimentally and to determine
whether the risk haplotype versus the intermediate C9orf72 repeats themselves are
driving increased C9orf72 gene expression, CRISPR/cas9 was used to modify the repeat
size in previously characterized induced pluripotent stem cells (iPSCs) from a nondiseased individual202. A repair template containing either 2 or 28 repeats was used to
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alter the size of the repeat expansion in iPSCs that normally have alleles of either 2 or 6
repeats (Figure 3.3a-b; Supplemental Figure 3.3). Clonal lines were derived by FACS and
were screened for changes in repeat size and for the presence of the knocked-in allele by
PCR followed by restriction enzyme digest (Figure 3.3b). Genotype, including repeat
size, was confirmed by repeat primed PCR (Figure 3.3c) and Sanger sequencing
(Supplemental Figure 3.4). Despite using a repair template with 28 repeats, several
different iPSC clones with repeat sizes ranging from 23 to 28 were obtained. Additional
isogenic iPSC clones were also obtained with two or six C9orf72 repeats.
Given that both neurons and glial cells are affected in CBD194, we used the dual SMAD
inhibition method203,213 to differentiate edited iPSCs with intermediate C9orf72
expansions and isogenic controls with small repeats into neural progenitor cells (NPCs)
as determined by uniform expression of the NPC marker Pax6 (Supplemental Figure 3.5).
RT-qPCR of these edited NPC lines showed a remarkably consistent pattern of higher
C9orf72 mRNA expression in clones with intermediate C9orf72 repeats compared to
isogenic controls with small repeats (Figure 3.3d). Consistent with the data from CBD
post mortem brain tissue, we again saw no change in the amount of variant 2 mRNA
(Figure 3.3e) but a robust increase in variant 3 mRNA levels in all intermediate C9orf72
repeat cell lines (Figure 3.3f-g). This effect was not an artifact of neuronal differentiation,
as undifferentiated iPSCs also exhibited increased C9orf72 mRNA levels (Supplemental
Figure 3.6). Thus, these experiments demonstrate a causal relationship between
intermediate C9orf72 expansions and increased C9orf72 mRNA levels.

Intermediate repeat carriers do not have RNA foci or DPR pathology
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Full expansion carriers have characteristic neuropathology in post mortem brain
and spinal cord tissue that includes nuclear RNA foci of G4C2 transcripts43 and
aggregates of dipeptide repeat proteins (DPRs) that co-stain with p6294. Staining for
DPRs using p62 antibody or DPR specific antibodies (GA, GP and GR) was carried out
on 125 CBD cases in hippocampus and/or cerebellum, including 9 cases with
intermediate repeats (repeat sizes 17-29, Figure 3.4a). Interestingly, all of these cases
were negative for the aggregates typically seen in full expansion cases (Figure 3.4a).
Additionally, RNA foci were not detected in CBD cerebellum tissues with intermediate
repeats, nor were they detected in cases with low repeat numbers (Figure 3.4b). In
comparison, full expansion FTD/ALS cases had abundant DPR aggregates together with
RNA foci in ~18% of nuclei. Thus, the major pathologic hallmarks of full expansion
carriers are not present in CBD cases, leading us to hypothesize that the underlying
mechanisms of intermediate expansions and CBD risk may be distinct from the large
repeat expansions that cause ALS/FTD.

Elevated C9orf72 protein and global gene expression changes in intermediate repeat
cell lines
To test whether C9orf72 protein expression is higher in cells with intermediate
repeats, protein expression was measured in isogenic repeat edited NPCs. NPC lines with
intermediate repeats exhibited a consistent ~40% increase in C9orf72 protein levels when
compared to isogenic low repeat number controls (Figure 3.5a-b). Thus, intermediate size
repeat expansions increase both C9orf72 mRNA and protein levels.
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To determine whether overexpression of C9orf72 in the context of intermediate
repeats alters expression of other genes, RNA sequencing was performed on 3 edited
intermediate NPC lines and 3 low repeat isogenic control lines (Supplemental table 3.2,
Supplemental file 1). We found 1,307 genes significantly downregulated (adjusted pvalue < 0.05 and fold change > 2) in intermediate repeat cell lines and 959 genes
upregulated (Figure 3.5c). Next, overrepresentation analysis was performed on gene
ontology pathways in the differentially expressed genes. Genes down regulated in
intermediate repeat cell lines (Figure 3.5d) are highly enriched for metabolic processes,
especially those involving nutrient catabolism. Genes upregulated in intermediate repeat
cell lines (Figure 3.5e) are enriched in vesicle trafficking and protein degradation
pathways including golgi vesicle transport, response to ER stress and autophagy. We then
looked in more detail at specific genes within the most highly dysregulated biological
processes. When categorizing vesicle trafficking genes according to their function78, there
is modest increase in expression of numerous endosomal/lysomal genes, including
C9orf72 (Figure 3.5f). Interestingly, there is a consistent and sizable decrease in
expression of genes involved in secretory pathways in intermediate repeat cell lines,
indicating a possible defect in vesicle secretion (Figure 3.5f). Additionally, key genes
involved in autophagy are modestly increased in intermediates (Figure 3.5g). However,
several genes that have been shown to regulate autophagy in response to nutrient
starvation214–216 and ER stress217 such as TMEM74 and TMEM74B are markedly
downregulated in intermediate repeat cells (Figure 3.5g), suggesting a defect in
autophagy under stress conditions. Finally, we compared the differentially expressed
genes in our dataset to previously published81,83 gene expression studies between control
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(low repeat) and full expansion cells derived from ALS/FTD patients. Interestingly, we
see a distinct group of dysregulated genes between control and intermediate repeat cells
than between control and full expansion cells (Figure 3.5h), indicating that different
processes are affected by intermediate expansions versus full expansions.

Over-expression of C9orf72 impairs starvation-induced autophagy
Next, a cell culture model was used to further validate the observed changes in
biological pathways in the RNA sequencing data and determine if these were in fact
caused by C9orf72 over expression. Since C9orf72 is known to regulate
autophagy68,75,76,218 and this pathway was altered in the RNA sequencing data, we
generated an inducible isogenic HeLa cell line expressing a single-copy of human
C9orf72 long isoform without the repeat expansion tagged with GFP and 6xHis-FLAG
tag. The transgene expression level is comparable, i.e., 1:1, to that of endogenous
C9orf72 and is under the tight control of tetracycline (Supplemental Figure 3.7 and 207).
Importantly, the transgene also associates with the autophagy initiation complex, thereby
confirming that the GFP-tagged C9orf72 recapitulates the known endogenous gene
function207. As a readout of autophagy, we utilized an LC3 (microtubule-associated
protein light chain 3)-based assay (Figure 3.6a). During autophagosome assembly, LC3-I
undergoes lipidation via conjugation with a phosphatidylethanolamine group to become
LC3-II 219,220. LC3-II is normally rapidly degraded during autophagy via fusion with the
lysosome, but blocking lysosome fusion allows for accumulation of LC3-II to serve as a
marker of autophagic activity221. Immunoblotting in C9orf72 overexpressing cells
revealed that basal LC3-II levels are ~20% higher in C9orf72 overexpressing cells
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compared to parental HeLa cells (lane NGM, normal growth medium, Figure 3.6b-c),
indicating that either autophagosome production is increased or lysomal degradation of
LC3-II is reduced under normal conditions. When autophagosome-lysosome fusion was
blocked with chloroquine (CQ)222, LC3-II accumulates at a higher level in CQ-treated
condition when compared to their untreated counterparts, and at a similar level between
the parental HeLa and C9orf72 overexpressing cells (Lane NGM+CQ, Figure 3.6b-c).
Interestingly, when autophagy was induced using nutrient-deficient medium, EBSS
(Earle’s balance salt solution), the accumulation of LC3-II was reduced by ~40% in the
C9orf72 overexpressing cells when compared with parental HeLa cells (Lane EBSS+CQ,
Figure 3.6b-c), suggesting that C9orf72 overexpression blocks starvation-induced
autophagy. To further corroborate the biochemical findings, a GFP-LC3 stable HeLa cell
line223 was transfected with C9orf72 construct linked via P2A peptide to mCherry to
better visualize the transfected cells. Consistent with the immunoblotting results above,
~50% more LC3-II puncta were observed in the C9orf72 overexpressing conditions in
normal growth media. (NGM panel, Figure 3.6d-e). However, there was ~30% reduction
of LC3-II puncta in C9orf72 overexpressing cells under starvation (EBSS+CQ panel,
Figure 3.6d-e), again indicating that there is a failure of autophagy initiation in starvation
conditions.
To more accurately measure the actual autophagic flux or rate, a time course
without and with chloroquine treatment was performed (Figure 3.7a). With the lysosomes
blocked, LC3-II accumulated at a similar rate in C9orf72 overexpressing cells under
normal conditions as the parental HeLa cells (Figure 3.7b-c, top blot). Under starvation
conditions, however, the rate of accumulation was markedly reduced (Figure 3.7b-c,
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bottom blot) compared to the parental HeLa cells. Taken together, these results suggest
that C9orf72 overexpression promotes autophagy under nutrient rich conditions but limits
the cell’s ability to induce autophagy during times of nutrient stress.

Discussion
In this study, we demonstrate that intermediate repeat expansions in C9orf72 may
be a genetic risk factor for CBD, thus broadening the spectrum of neurodegenerative
diseases implicated by this gene. This study highlights the importance of using autopsy
confirmed cases to better understand the genetics of neurodegenerative diseases that have
similar or overlapping clinical manifestations. Although intermediate repeats are found in
only a small percentage of CBD patients, the magnitude of risk conferred by intermediate
repeats is comparable or greater than other known genetic risk factors for CBD224. This
study assembled the most CBD cases yet tested, and due to the rarity of CBD, a
replication cohort is not yet available for follow-up analysis. While we established an a
priori hypothesis based on the previously established but arbitrary cutoff of 17 repeat
units or larger to define intermediate expansion carriers, our findings suggest that both
CBD risk and C9orf72 expression increases in an additive manner with increasing repeat
length where perhaps C9orf72 intermediate expansions could be defined as at least 10
units. Interestingly, initial reports of C9orf72 repeat mutation cohorts, defined at that time
as at least 30 repeats, included one case of autopsy-confirmed CBD225. We did not detect
any expansions larger than 29 repeats in our CBD cohort, and intermediate expansion
carriers did not have the characteristic RNA foci and dipeptide repeat pathology seen in
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full expansions. Future studies will need to further define the size threshold that
determines whether carriers are more likely to develop risk for CBD versus ALS/FTD.
C9orf72 joins a list of other repeat expansion containing genes in which the
length of the repeat confers a pleiotropic effect on the disease phenotype. For instance,
intermediate length CGG repeats in the gene FMR1 result in the neurodegenerative
disease Fragile X-associated tremor/ataxia syndrome (FXTAS) linked to toxicity of
repeat RNA226, whereas full expansions lead to near complete silencing of FMR1 and the
neurodevelopmental disorder Fragile X Syndrome50. Similarly, intermediate CAG
expansions in Ataxin-2 are a risk factor for ALS227, whereas full expansions cause
spinocerebellar ataxia type 2228. For C9orf72, large expansions cause ALS/FTD43,44,
whereas we demonstrate that intermediate expansions confer ~3.5 fold higher risk for
CBD. Full expansions mutations in C9orf72 have been associated with reduction of
C9orf72 gene expression and a gain of repeat associated pathology including nuclear
repeat RNA accumulation and dipeptide repeat protein production43,62,63,115. In contrast,
we show that intermediate expansions cause an increase in C9orf72 mRNA levels in both
CBD post mortem cerebellum and knock-in isogenic neural cell lines. This mechanism is
also supported by publicly available SNP eQTL data, which shows that numerous SNPs
on the expansion haplotype are associated with increased C9orf72 expression. Thus, it
appears that maintaining proper levels of C9orf72 may be necessary for proper neuronal
function, with increased expression observed in CBD patients and decreased expression
observed in ALS/FTD patients.
C9orf72 is thought to function as Rab guanine exchange factor55, which
participates in a host of vesicle trafficking pathways65. C9orf72 has been shown to
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regulate endocytosis56, vesicle secretion70, intracellular trafficking56,58,70,115 and
autophagy67–69,76,218,229. Indeed, we observe numerous gene expression changes in all of
these vesicle trafficking pathways in knock-in NPCs with intermediate expansions. The
large number of significant gene expression changes detected in this study is likely due to
the depth of sequencing (~100 million reads/sample) and the use of isogenic CRISPR
edited controls, which removes variability due to genetic background. Particularly
striking changes were observed in genes involved in vesicle secretion and autophagy. The
involvement of autophagy pathways in numerous neurodegenerative diseases has been
well documented 65, and increased levels of C9orf72 may enhance CBD risk by
disrupting autophagy pathways necessary for responding to stress. C9orf72 has been
shown to regulate autophagy initiation through the ULK1 complex67,75,207, and we observe
increased expression of autophagy initiation genes in the intermediate repeat knockin
NPCs. Interestingly, over expression of C9orf72 seems to increase autophagy initiation
under normal conditions, but inhibits autophagy induction under nutrient stress. Several
other studies have implicated C9orf72 as regulator of the cellular stress response71,73,76,77,
and we observe dysregulation of genes involved in the ER stress response and nutrient
biosynthesis pathways in intermediate repeat knockin NPCs. In particular, the gene
TMEM74 and its paralog TMEM74B were highly downregulated in C9orf72 NPCs with
intermediate repeats. TMEM74 has been shown to be a potent activator of autophagy
induced via nutrient starvation214 and is thought to function via a unique pathway that
does not require initiation via the canonical ULK1 autophagy initiation complex215. This
alternative initiation pathway may be affected by increased C9orf72 levels and could
explain why we observe an autophagy defect in C9orf72 over expressing cells under
85

nutrient starvation. Future studies will need to further define the molecular mechanisms
by which C9orf72 overexpression alters specific autophagy pathways.
Overall, the findings presented here illustrate the complexity of C9orf72 repeat
expansion mutations, with the length of expansion conferring risk for different
neurodegenerative diseases via opposing mechanisms. Notably, the proportion of CBD
cases with intermediate C9orf72 repeats is still relatively low (~4%) indicating that the
overall genetic risk associated with intermediate repeats is modest. Likewise, given that
CBD is a rare disease, an otherwise normal individual harboring an intermediate repeat is
unlikely to develop CBD. Finally, these results indicate that autophagy pathways are
dysregulated by elevated C9orf72 levels and suggest a link between C9orf72 expression
and neurodegenerative disease.
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Figures

Figure 3.1: C9orf72 repeat sizing of CBD. a) Example capillary electrophoresis traces
of CBD cases measured from genomic DNA using a fluorescent PCR assay with
genotypes of 2,2 (top), 2,18 (middle) or 9,20 (bottom). b) Summary statistics for repeat
size screening of CBD cases (n = 708 alleles) and previously published controls (n =
11,774 alleles)123. Fisher’s exact test: OR = 3.59, 95% CI = 1.80 – 6.65, p = 0.000238. c)
Allele frequencies of repeat sizes in CBD cases and controls. The number of alleles in the
CBD cohort for each size is depicted above the bars. d) Results of Fisher’s exact test
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between CBD cases and controls at each allele size cutoff. Dotted gray line represents p <
0.05 significance level.
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Figure 3.2: Effect of intermediate repeats on C9orf72 expression. a) Diagram of the
C9orf72 locus with mRNA and protein isoforms. Transcription start sites (TSS) are
labeled for each mRNA variant on the genomic DNA. Colored arrows on the mRNA
depict primers used for RT-qPCR. b) Correlation between total C9orf72 repeat size (left)
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or largest allele (right) and C9orf72 mRNA levels from all variants measured by RTqPCR using RNA from CBD patient cerebellum (Total repeats: n = 29, R2 = 0.276, p =
0.0034; Largest allele: n = 29, R2 = 0.1613, p = 0.0308). Data is normalized to samples
with 4 total repeats. c) Correlation between total C9orf72 repeat size (left) or largest
allele (right) and variant 2 mRNA levels (Total repeats: n = 29, R2 = 0.00496, p = 0.717;
Largest allele: n = 29, R2 = 0.04432, p = 0.2730). d) Correlation between total C9orf72
repeat size (left) or largest allele (right) and variant 3 mRNA levels (Total repeats: n =
29, R2 = 0.667, p < 0.0001; Largest allele: n = 29, R2 = 0.4874, p < 0.0001). e)
Correlation between total C9orf72 repeat size (left) or largest allele (right) and the variant
3 mRNA to variant 2 mRNA ratio (Total repeats: n = 29, R2 = 0.849, p < 0.0001; Largest
allele: n = 29, R2 = 0.8869, p < 0.0001). f) Genotyping results for rs3849942 in the CBD
patient genomic DNA cohort (n = 708 alleles). The A allele is associated with
intermediate and full length repeat expansions. g) SNP eQTL data from the Gtex project
showing the effect of rs3849942 on C9orf72 expression in basal ganglia (left, p = 9.00E07) and tibial nerve (right, p = 2.80E-16). For box plots, center line indicates median,
boxes are upper and lower quartiles, error bars are standard error of the mean. Numbers
of samples are indicated below each group. h) Normalized GTEx eQTL effect size from
cortex and basal ganglia on C9orf72 expression for all 20 SNPs in the consensus repeat
expansion risk haplotype (from Mok et al. 2012212). * indicates SNPs with a significant
effect on C9orf72 expression. Red dotted line indicates the location of the C9orf72 repeat
expansion.
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Figure 3.3: CRISPR/cas9 knock-in of intermediate repeats into iPSCs. a) Diagram of
C9orf72 genomic locus and double stranded repair templates used for knocking in
intermediate repeats. Black triangle represents the CRISPR/cas9 cut site. Black arrows
indicate the PCR primers used in (b). Red boxes indicate the G4C2 repeat. Blue boxes
indicate the 2 bp substitution included in the repair templates to mutate the Cas9 PAM
site and generate a PvuII restriction enzyme site. b) PCR (top) and PvuII digest (bottom)
of CRISPR edited iPS cell lines using PCR primers spanning the CRISPR cas9 cut site
and repeat expansion. Digestion of the PCR product indicates that HDR occurred. c)
Capillary electrophoresis traces of repeat primed PCR from CRISPR edited iPSCs. d-g)
RT-qPCR from the indicated variants of C9orf72 from neural progenitor cells
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differentiated from CRISPR edited iPSCs. Light bars correspond to low repeat lines
while black bars correspond to intermediate repeat lines. N = 3 biological replicates per
cell line; ANOVA (All variants: F = 18.3, p = 0.0001; Variant 2: F= 2.9, p = 0.08;
Variant 3: F = 216.0, p < 0.0001; V2/V3: F = 460.0, p < 0.0001) followed by Bonferroni
post hoc test between low and intermediate repeat cell lines. **p < 0.01, ***p < 0.001,
****p < 0.0001. Error bars are standard error of the mean.
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Figure 3.4: Absence of repeat pathology in intermediate expansion cases. a)
Representative Immunohistochemistry images of non-expanded control (n=4 cases) or
non-expanded CBD (n = 116 cases), intermediate expansion CBD (n = 9 cases), and full
expansion FTD/ALS (n = 5 cases) post mortem cerebellar samples using anti-GA or p62
antibodies. Intermediate expansion carriers were also negative for GP/GR aggregates.
Scale bar 10μm. b) Representative fluorescence in situ hybridization images of nonexpanded control (n=4 cases) or non-expanded CBD (n = 12 cases), intermediate
expansion CBD (n = 5 cases), and full expansion FTD/ALS (n = 5 cases) post mortem
cerebellar samples using a probe complimentary to the G4C2 repeat. Scale bar 5μm.
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Figure 3.5: Elevated C9orf72 protein levels and gene expression changes in
intermediate repeat NPCs. a) Western blot of protein expression from CRISPR edited
NPCs. N = 2 low repeat and 3 intermediate repeat number cell lines. C9orf72 antibody
was validated in HEK293T cells transfected with C9orf72 overexpression plasmid (Lanes
1-2). Representative blot of 2 technical replicates is shown. b) Quantification of C9orf72
protein levels from repeat edited NPCs. Protein expression was normalized to GAPDH as
a loading control and the average of 2 technical replicates is reported. N = 2 low repeat
and 3 intermediate repeat number cell lines. Two tailed t-test, p = 0.0145. Error bars are
standard error of the mean. c) RNA sequencing analysis of 3 low repeat NPC lines (max
repeat size 2 or 6) and 3 intermediate repeat (max repeat size 23, 27 or 28) NPC lines.
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Differentially expressed genes with an adjusted p-value < 0.05 and greater than 2 fold
change are depicted as red dots. d-e) Overrepresentation analysis of biological processes
on differentially downregulated genes (d) or upregulated genes (e) in NPCs with
intermediate repeats. Labels highlight the top 10 most significant biological processes. f)
Changes in gene expression of genes involved in vesicular trafficking. All genes shown
are significantly differentially expressed (adjusted p < 0.05) between low repeat and
intermediate repeat NPCs. g) Changes in gene expression of genes involved in
autophagy. All genes shown are significantly differentially expressed (adjusted p < 0.05)
between low repeat and intermediate repeat NPCs. h) Comparison of overlap in
differentially expressed genes between low repeat NPCs versus intermediate repeat NPCs
(this study) or low repeat vs full expansion neurons from patient derived iPSCs from two
previous studies 81,83. Only genes with adjusted p < 0.05 and fold change > 2 were used in
this comparison.
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Figure 3.6: Autophagy defects in inducible C9orf72 over-expressing cells
a) Schematic of experimental procedure for LC3-II protein detection in C9orf72 HeLa
stable cells. b) Representative western blot showing LC3-II expression levels of parental
HeLa cells and C9orf72 cells first treated with treated with tetracycline to induce C9orf72
transgene expression then with EBSS and/or CQ for 1 hour. c) Bar chart corresponding
to (b) showing pooled data of LC3-II protein levels expressed as fold change over
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parental HeLa cells in normal growth media without CQ treatment. Data represents
three independent experiments with * p<0.05, Student’s t-test. d) Schematic of
experimental procedure for the detection of LC3-II puncta using fluorescence
microscopy in parental HeLa cells overexpressing GFP-LC3 and mCherry (control)
or C9orf72-P2A-mCherry plasmids. The cells were treated with NGM, EBSS,
EBSS+CQ or NGM+CQ for 2 hours and green puncta associated with GFP-LC3 in
mCherry-overexpressing cells were analyzed using ImageJ particle count. At least 25
cells were analyzed per treatment group. Scale bar = 20 µm. e) Bar chart corresponds to
the average LC3 puncta count in (d) with * p < 0.05, Student’s t-test. Error bars represent
standard error of the mean (S.E.M).
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Figure 3.7: Kinetics of starvation induced autophagy in C9orf72 over-expressing
cells. a) Schematic of time-course experiments on autophagy in C9orf72 HeLa stable
cells. b) Representative western blot showing LC3-II expression levels of parental HeLa
cells and C9orf72 cells first treated with tetracycline to induce C9orf72 transgene
expression then with either normal growth media (NGM)+CQ or EBSS+CQ for 0, 1, 2,
and 3 hours. c) Time course chart corresponding to (b) showing pooled data of LC3-II
protein levels expressed as fold change over respective controls, i.e. parental HeLa cells
or C9orf72 cells grown in normal growth media without CQ treatment. Data represents
three independent experiments with error bars representing standard error of the mean
(S.E.M).
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Supplemental Figures and Tables

Supplemental Figure 3.1: Repeat Expansion sizes in the CBD post mortem cerebellum
cohort. Repeat sizes from CBD post mortem cerebellum detected using fluorescent PCR
followed by capillary electrophoresis. N = 47 cases.
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Supplemental Figure 3.2: DNA methylation analysis at the C9orf72 promoter of CBD
post mortem cerebellum cohort and comparison to full expansion cases. DNA
methylation was measured using HhaI digest followed by qPCR on CBD cases (n = 47)
and full expansion ALS/FTD cases (n= 20). Within the CBD case group, there is no
significant association between repeat size and DNA methylation of C9orf72 (R2 =
0.01012, p = 0.5010).
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C9orf72 Homologous Repair template (5’ to 3’)
CCGCTAGGAAAGAGAGGTGCGTCAAACAGCGACAAGTTCCGCCCACGTAAAAGATGACGCTTGGTGTGTCA
GCCGTCCCTGCTGCCCGGTTGCTTCTCTTTTGGGGGCGGGGTCTAGCAAGAGCAGGTGTGGGTTTAGGAGG
TGTGTGTTTTTGTTTTTCCCACCCTCTCTCCCCACTACTTGCTCTCACAGTACTCGCTGAGGGTGAACAAG
AAAAGACCTGATAAAGATTAACCAGAAGAAAACAAGGAGGGAAACAACCGCAGCCTGTAGCAAGCTCTGGA
ACTCAGCTGTCGCGCGCTAGGGGCCGGGGCCGGGGCGTGGTCGGGGCGGGCCCGGGGGCGGGCCCGG
GGCGGGGCTGCGGTTGCGGTGCCTGCGCCCGCGGCGGCGGAGGCGCAGGCGGTGGCGAGTGGGTGAGTGAG
GAGGCGGCATCCTGGCGGGTGGCTGTTTGGGGTTCGGCTGCCGGGAAGAGGCGCGGGTAGAAGCGGGGGCT
CTCCTC

Supplemental Figure 3.3: Homologous template and gRNA sequence used to edit the
endogenous C9orf72 repeat expansion size. Homologous template containing either 2 or
28 G4C2 repeat units was cloned via PCR and inserted into P-gem Easy T vector. The
20bp CRISPR gRNA sequence is underlined and the 2 bp mutation which destroys the
PAM site and introduces a PvuII restriction enzyme site is highlighted in red. The G4C2
expansion site is in bold (shown here is 2 repeat units).

101

Supplemental Figure 3.4: Sanger sequencing of repeat edited iPSCs. Representative
chromatograms of CRISPR edited iPSCs that were PCR cloned and Sanger sequenced.
All CRIPSR edited cell lines included in this study were matched to have the same 8 bp
deletion on the non-repeat edited allele, likely due to non-homologous end joining.
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Supplemental Figure 3.5: Characterization of iPSC derived neural progenitor cells.
Immunofluorescence images of day 12 post neural induction CRISPR edited NPCs
stained with either pax6 (NPC marker) or Oct4 (iPSC marker). The number separated by
a comma indicates repeat sizes of each allele in the NPC cell lines.
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Supplemental Figure 3.6: C9orf72 variant 3 mRNA levels from undifferentiated, repeat
edited iPSCs. 1 way ANOVA followed by Bonferroni multiple comparison test. ****p <
0.0001. All intermediate repeat cell lines are significantly different than both low repeat
controls
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Supplemental Figure 3.7: Expression of C9orf72 transgene is comparable to the
endogenous C9orf72 and is induced by tetracycline. a) Immunoblots of parental HeLa
cells and the inducible isogenic C9orf72 cells used in this study. Both groups were
treated with tetracycline for 18 hours. A polyclonal antibody (Santa Cruz Biotechnology,
sc-138763) was used to detect the endogenous C9orf72 (black arrowhead) and the
C9orf72 transgene (green arrowhead). The level of transgene is comparable to
endogenous C9orf72 and the levels of endogenous C9orf72 are similar between parental
HeLA cells and C9orf72 inducible cells. b) Immunoblots of C9orf72 transgene with or
105

without tetracycline induction. Inducible isogenic C9orf72 cells were cultured without (-)
or with (+) tetracycline and subjected to GFP-immunoprecipitation to enrich for C9orf72
transgene. Input and GFP-immunoprecipitants were probed with FLAG antibody to
detect C9orf72 transgene. C9orf72 transgene only be detected after tetracycline
treatment.

Table 3.S1: Primers and CRISPR gRNAs

Forward Primer Sequence

Reverse Primer Sequence

Assay

6FAM-CAAGGAGGGAAACAACCGCAGCC

GCAGGCACCGCAACCGCAG

Sizing of C9orf72 Repeats

6FAM-AGTCGCTAGAGGCGAAAGC

TACGCATCCCAGTTTGAGACG

Repeat Expansion
Detection
Repeat Expansion
Detection

TACGCATCCCAGTTTGAGACGGGGGCCGGGGCCGGGGCCGGGG

CCCACTTCATAGAGTGTGTGTTG

TTCCATTCTCTCTGTGCCTTC

Total C9orf72 mRNA (all
variants)

CGGTGGCGAGTGGATATCTC

TGGGCAAAGAGTCGACATCA

C9orf72 variant 2 mRNA

GCAAGAGCAGGTGTGGGTTT

TGGGCAAAGAGTCGACATCA

C9orf72 variant 3 mRNA

GAGGAGAGCCCCCGCTTCTAC

CCGCTAGGAAAGAGAGGTGCG

CACCGTGTAGCAAGCTCTGGAACTC

aaacGAGTTCCAGAGCTTGCTACAC

CAGTGTGAAAATCATGCTTGAGAGA

TTTGTGCTTGGTAGGCAGTG
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Template cloning and
HDR analysis of repeat
edited iPSCs
CRISPR gRNA sequences
for repeat editing
DNA methylation analysis

Table 3.S2: RNA sequencing of intermediate repeat NPCs raw read counts
Sample

Short Repeat 1
Short Repeat 2
Short Repeat 3
Intermediate Repeat 1
Intermediate Repeat 2
Intermediate Repeat 3

Repeat Size

Total Reads

2,6
2,2
2,6
2,23
6,28
27,27

109337673
108537553
118024548
125527873
121998215
131039648

Table 3.S3: Evaluation of C9orf72 Risk haplotype marker rs3849942 A in CBD
cases vs control populations

Cohort

rs3849942 A Risk Allele
Frequency

CBD cases

159 / 698 (22.78%)

Controls from Beck et
al. 2013

2,597 / 10,400
(24.97%)

X = 1.568, p =
0.2105 (n.s.)

Gobal populations
(dbSNP)

35,048/162,186
(21.6%)

X = 0.4124, p =
0.5207 (n.s.)

Chi Square Test

2
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2

Odds Ratio (95%
CI)

0.8863
(0.7385-1.064)
1.064 (0.89131.271)

Table 3.S4: Repeat sizes of CBD cases with intermediate expansions
Case Number
1
2
3
4
5
6
7
8
9
10
11
12
13

Repeat Size Allele 1
2
2
2
2
6
6
9
2
5
2
14
2
2

Repeat Size Allele 2
29
26
22
22
21
21
20
18
17
17
17
17
17

Table 3.S5: Comparison of CBD cohort vs Theuns. et al 2014 controls at each allele
cutoff
Repeat Size Cutoff
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

P-Value (Fisher Exact Test)
0.876300
0.640200
0.638300
0.700700
0.963300
0.499400
0.209900
0.026040*
0.108800
0.032910*
0.073220
0.128100
0.061270
0.004179**
0.0002376****
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Odds Ratio
0.9853727
0.9612321
0.9609401
0.9653403
1.006105
1.064384
1.182729
1.359480
1.292946
1.498095
1.489279
1.491891
1.757263
2.512414
3.591016

Chapter 4: Conclusions and Future Directions
This thesis explored several different pathways related to how repeat expansions
in C9orf72 contribute to neurodegenerative disease. First, we developed a novel method
of targeted methylation in order to model DNA hypermethylation that is observed in
ALS/FTD patients with the C9orf72 repeat expansion. This work led to several important
conclusions regarding the relationship between DNA damage and DNA methylation.
DNA methylation is linked to DNA double strand break repair
It has long been thought that DNA methylation and DNA repair pathways were
related due to the fact that chromosomal breaks correlate with changes in DNA
methylation131. This idea was bolstered by evidence from reporter constructs that double
strand breaks can directly induce DNA methylation167–169. Prior to this work, however, no
study had shown that this process also occurs at endogenous genes. It’s possible that
methylation of exogenous DNA could be a defense response against foreign DNA such
as viruses or transposable elements. The work presented here shows that methylation
following DNA damage also occurs at endogenous genes and thus is a more generalized
response than originally realized. This finding may help explain why DNA methylation at
specific sites increases with age132, as DNA damage due to oxidative stress is known to
increase with age as well230. Future studies using multiplexed CRISPR gRNAs targeted
to CpG islands could determine which loci genome-wide are prone to DNA methylation
following DNA cleavage. These results would have important implications for cancer and
other aging related diseases.
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Another important finding relating to DNA methylation and DNA repair
pathways is that methylation marks can be copied from an exogenous repair template into
the genome. This was dependent on the process of homology directed repair (HDR), and
the efficiency of methylation correlated with the length of the repair template. This
process was also dependent on DNMT1, DNMT3a, DNMT3b and UHRF1. It was
initially surprising that both the maintenance methyltransferase enzyme (DNMT1) and
the de novo methyltransferase enzymes (DNMT3a/3b) were all involved in copying of
methylation during HDR. However, it has been suggested that the methyltransferase
enzymes have more overlapping functionality than previously realized231. Additionally,
we did not determine the exact contribution of these enzymes to methylation via the
different repair pathways. It is possible that the de novo methyltransferases are
responsible for targeting methylation following NHEJ, whereas the DNMT1/UHRF1
complex is responsible for copying methylation from the repair template. Future
experiments will need to clarify this point.
Additionally, it is unclear why only ~50% of CpGs are methylated in the
endogenous gene following HDR. One possibility is that methylation is not copied during
a subset of repair events. This is possible if some DNA is repaired via the non-canonical
synthesis dependent strand annealing pathway (SDSA). SDSA differs from canonical
HDR in that it only utilizes limited synthesis from one strand of the repair template rather
than copying from both strands166,232. Since copying of methylation is likely to occur
during DNA synthesis from the methylated template, repair via SDSA would restrict
copying of methylation to small regions around the break site. Future studies should
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explore the sub-pathways of HDR more closely in order to improve efficiency of
methylation following HDR.
Hypermethylation of the C9orf72 promoter leads to gene silencing
Another key finding from Chapter 2 is that DNA methylation of the C9orf72
promoter leads directly to a gain in histone H3K9 trimethylation and a reduction of
C9orf72 mRNA levels in ALS patient derived iPS cells. Furthermore, the largest
reduction in mRNA levels occurred from the transcription start site closest to the CpG
island, suggesting that the proximity of DNA methylation to the transcription start site
may influence transcriptional activity. This transcript (V3) also contains the repeat
expanded RNA, and thus preferential reduction of this transcript may ameliorate the gain
of function toxicity associated with the expanded RNA. Future studies using this newly
established cellular model of DNA hypermethylation are needed to better understand how
a reduction in C9orf72 mRNA affects the balance between a loss of normal C9orf72
protein function and inhibition of the toxic gain of function pathway.
HARDEN can be applied for targeted methylation of APP
A major unanswered question is whether HARDEN is a general method that can
be applied to other genomic loci. It is known that genes with repeat expansions are prone
to DNA methylation, so it is possible that C9orf72 might be more amenable to targeted
DNA methylation. To determine if HARDEN can be applied to another locus besides
C9orf72, we targeted a CpG island in the promoter region of APP. APP encodes amyloid
precursor protein, a key protein involved in Alzheimer’s disease (AD) pathogenesis233.
111

APP is cleaved by proteases to generate amyloid beta peptides, which are a major
component of amyloid plaques found in AD patient brain233. Amyloid beta production is
thought to play a central role in AD pathogenesis, as mutations in APP that increase
amyloid beta levels are known to cause dominantly inherited early-onset AD234. Several
studies have investigated the DNA methylation status of the CpG island upstream of APP
but have come to differing conclusions as to whether APP is differentially methylated in
AD patients235–238. Thus, it may be beneficial to generate cellular models of DNA
methylation at this locus to determine the effects of DNA methylation on APP
expression.
As a proof of principle, we applied the HARDEN system to APP by inducing a
double strand break with Cas9 and providing a methylated repair template (Figure 4.1,
A). The repair template also includes a 12 base pair mutation that allows for PCR
amplification of only the DNA that has undergone HDR using the repair template (Figure
4.1, B). Bisulfite cloning of amplicons repaired with an unmethylated or methylated
template was then carried out to assess the DNA methylation pattern of repaired DNA
(Figure 4.1, C). This analysis revealed that DNA repaired with the methylated template is
highly enriched for methylation, with the CpG sites closest to the cut site exhibiting
levels of methylation exceeding 50% (Figure 4.1, C-D). In some clones, methylation was
copied more than 500 base pairs downstream from the cut site (Figure 4.1, C-D). In sum,
~45% of amplicons (10/22) gain dense DNA methylation when repaired with a
methylated template, compared to no amplicons (0/23) repaired with the unmethylated
template (Figure 4.1, E). These results indicate that DNA methylation can be copied
during HDR and confirm that HARDEN is a generalizable method that can be applied to
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other genes besides C9orf72. Future work using these epigenetically edited cells could
determine whether hypermethylation of this CpG island reduces APP expression and
downstream amyloid beta production.

Figure 4.1: Targeted DNA methylation of APP via HARDEN. A) Diagram of APP gene locus
showing CpG island, gRNA targeting site (black triangle) and bisulfite primers (Red and black arrows)
used to amplify only DNA that incorporates a 12bp mutation (red box) from the template. B) Bisulfite PCR
of HEK293T cells transfected with No gRNA plasmid, APP gRNA + unmethylated template or APP gRNA
+ methylated template. n = 2 biological replicates. Primer location is indicated in (A). C) Bisulfite
sequencing of cloned amplicons from (B). Each column represents a CpG site in the ~600bp amplicon.
Grey boxes indicate unmethylated cytosines whereas black boxes represent methylated cytosines. n = 23
sequences for APP gRNA+ unmethylated template group and n = 22 sequences for APP gRNA+
methylated template group. D) Quantification of mean methylation at each CpG site in the amplicon (73
total CpG sites) depicted in (C). n = 23 sequences from unmethylated template group and n = 22 sequences
from methylated template group. E) Number of highly methylated amplicons (>20% methylation) from
bisulfite sequencing depicted in (C). n = 23 sequences for unmethylated template group and n = 22 for
methylated template group. 10 amplicons are highly methylated in the methylated template group vs 0
amplicons in the unmethylated template group. ***p = 0.0002; Fisher’s exact test (two sided).
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In chapter 3, we explore the genetic risk associated with C9orf72 intermediate
repeat expansions and how this relates to gene expression. Prior to this study, there was
no clear indication of whether intermediate repeats in this gene were a risk factor for
neurodegenerative disease. This study was not only the largest exploration of genetic risk
for the neurodegenerative disease corticobasal degeneration (CBD), but it also revealed
key insights into the molecular pathways that may be driving disease risk.
C9orf72 intermediate repeat expansions are a risk factor for corticobasal
degeneration
Perhaps the most important finding of chapter 3 was that intermediate repeats in
C9orf72 are a risk factor for corticobasal degeneration. Prior to this work, there was
conflicting evidence as to whether C9orf72 was a risk factor for other neurodegenerative
diseases such as Parkinson’s disease125,126. We found that expansion carriers with
intermediate repeats ranging from 17-30 units have more than 3-fold higher risk for CBD.
Importantly, our study also suggests a new definition of what should be considered an
“intermediate” size repeat expansion in C9orf72, as we observe increasing risk for CBD
beginning at just 10 repeats. This work also highlights the importance of an autopsy
confirmed cohort for genetic analysis of neurodegenerative diseases that have similar
clinical characteristics. It remains important to note, however, that CBD is a rare disease
and thus a given intermediate expansion carrier in the general population has relatively
low risk for developing CBD. The rarity of CBD made it impossible to assemble a large
enough replication cohort for this association. When more cases become available in the
future, a replication study should be conducted.
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Intermediate length repeat expansions increase C9orf72 expression
Another significant finding in this thesis work is that intermediate length repeat
expansions have the opposite effect on C9orf72 expression as the full length expansions.
It is well established that the full length expansions that cause ALS/FTD result in
decreased C9orf72 mRNA and protein levels44,62,63,115. Our work shows that C9orf72
expression is actually increased in intermediate expansion carriers. This was true in both
patient post mortem brain tissue and in knock-in isogeneic neural progenitor cells.
Furthermore, it appears that expression increases with increasing total repeat number in
an additive manner. This corresponds well with the observation that CBD risk also
increases with increasing repeat number and suggests that increased C9orf72 expression
may be driving disease risk (Figure 4.2).

Figure 4.2: Effect of C9orf72 repeat size on expression and disease risk. C9orf72 expression
increases linearly from low repeats (2-8 units) to intermediate repeats (10-30), but decreases in
full expansion carriers. Risk for CBD increases with increasing repeat number (up until 30
repeats), whereas ALS/FTD develops in carriers with ~70 repeats or more. CBD risk may result
from decreased tau clearance in intermediate repeat cells due to autophagy defects. ALS/FTD
may be driven by toxic RNA and protein species in the context of low C9orf72 expression.
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This work reinforces previous findings in carriers with intermediate GCC repeats
in the FMR1gene. In this gene, individuals with 55-200 repeats are at risk for the
neurodegenerative disease fragile X-associated tremor/ataxia syndrome (FXTAS)239.
FXTAS patients exhibit increased FMR1 expression whereas larger expansions result in
epigenetic silencing and the neurodevelopmental condition fragile X syndrome50,240–242.
Future studies should delve into the mechanisms underlying how intermediate expansions
cause upregulation of C9orf72. One possibility is that the GC rich nature of intermediate
repeats promotes transcription from upstream transcription start sites (TSS) that are more
active. Indeed, our data suggests that the increase in C9orf72 mRNA levels is driven
primarily through an increase in variant 3 abundance, which is normally the minor
isoform and has a TSS upstream from the repeat expansion. A similar mechanism has
been observed in FXTAS patients, where a shift to an upstream TSS results in higher
levels of transcription240,243. Another possibility is that intermediate expansions lead to
increased mRNA stability of repeat containing transcripts, although this is not observed
in FXTAS240. Future work should clarify whether increased levels of C9orf72 are due to
enhanced transcription, reduced mRNA degradation or increased translation.
Increased C9orf72 expression disrupts autophagy
A final key finding from this thesis work is that increased expression of C9orf72
results in an ablated autophagy response under nutrient stress conditions. We found that
knock-in neuronal progenitor cells with intermediate repeats exhibit gene expression
changes in key autophagy and endo-lysosomal pathways. The dysregulated genes also
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included genes responsible for promoting autophagy under stress conditions. These
results were reinforced by experiments in a C9orf72 over-expression cell culture model.
We found that C9orf72 over-expression promotes autophagy under normal conditions but
actually blocks autophagy induction during nutrient starvation. These finding suggest a
model where proper levels of C9orf72 are required for an appropriate stress response.
While we only examined the response to nutrient deprivation, other studies have
implicated C9orf72 in the response to other stressors including ER stress, oxidative stress
and heat shock71,76,77. Thus, an ablated stress response in the context of aging or other
insults may underlie the neurodegenerative disease risk associated with C9orf72
intermediate expansions. Future studies will need to further define how differing levels of
C9orf72 can both promote and inhibit autophagy under different conditions.
C9orf72 expression and tau aggregation
A final area for future investigation is to determine how increased expression of
C9orf72 relates to the disease pathology seen in CBD. The major pathology found in
CBD patients is neuronal and astrocytic tau aggregates244. In preliminary experiments, we
asked whether increasing C9orf72 expression may alter tau aggregation. We utilized a
previously developed245 “tau biosensor” cell line that stably expresses a mutant tau repeat
domain (P301S) fused to fluorescent reporters. When seeded with purified tau from post
mortem brain, the tau reporters aggregate and generate a FRET signal that is detected by
flow cytometry (Figure 4.3, A)245. We overexpressed C9orf72 protein at either low or
high levels in these cells using constructs devoid of the intronic G4C2 repeat domain and
transduced them with tau from CBD patient post-mortem brain (Figure 4.3, B). After
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measurement of FRET via flow cytometry, we found that FRET intensity appeared to
increase in a dose dependent manner with increasing amounts of C9orf72 overexpression (Figure 4.3, C) but was only significantly higher when using a codon
optimized construct with large amounts of over-expression. These results suggest that
high levels of C9orf72 over-expression may promote increased tau aggregation. Future
studies in more physiological models of tau pathology will be needed to determine
whether this effect is specific for C9orf72 and represents a real mechanism of disease
risk.

Figure 4.3: Effect of C9orf72 over-expression on tau aggregation. A) Overview of tau
biosensor cells. HEK293T cells stably express mutant (P301S) tau repeat domain fused to a
fluorescent protein. When seeded with tau from CBD patient brain, tau aggregation can be
measured as a FRET signal by flow cytometry. B) Western blot of C9orf72 in tau biosensor cells
that were transfected with either a WT or HA-tagged codon optimized C9orf72 encoding plasmid.
C) Normalized FRET signal measured by flow cytometry of tau biosensor cells transfected with
empty vector or C9orf72 overexpression constructs. Data was normalized to empty vector
control. n = 4 experiments. 1 way ANOVA (p = 0.0014) followed by Bonferroni post hoc test.
**p < 0.01. In collaboration with Jessica Phan.
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Final Remarks
The work presented here highlights the complexity of neurodegenerative diseases
and the challenges faced by researchers in trying to define the underlying molecular
mechanisms. Here, we show that mutations within a single gene that are known to cause
ALS and FTD can also serve as a risk factor for a third neurodegenerative disease, CBD.
Furthermore, the length of the repeat expansion and the epigenetic status of the locus
serve as disease modifiers, thereby adding additional complexity. Despite this, our work
demonstrates that common molecular pathways emerge in these diseases such as protein
aggregation, cellular stress responses, autophagy and regulation of gene expression. We
hope that the novel method of targeted DNA methylation presented here and the new
insights into intermediate C9orf72 repeat expansions may further the research
community’s efforts to find cures for these fatal diseases.
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APPENDIX

Protocols
CRISPR gRNA Cloning
1. Design gRNAs and add BbsI overhangs:
a. Add CACCG on 5’ end of top oligo
b. Add C on 3’ end and CAAA on 5’ end of bottom oligo
2. Resuspend oligos in milliqH20 to 100uM
3. Oligo Annealing/Phosphorylation Reaction:
Component
Amount (ul)
X 4 reactions
x100uM sgRNA oligo Top Strand
1
100uM sgRNA oligo Bottom Strand
1
10X NEB T4 DNA Ligation Buffer
1
4
NEB T4 PNK
1
4
Milliq H2O
6
24
TOTAL:
10ul
8ul + 1ul F + 1ul R
Thermocycler program: CRISPR Anneal
Cycling Conditions: 37⁰ for 30mins, 95⁰ for 5mins, Ramp to 25 at 5⁰/s (2.5% on Veriti thermocycler)
4.
5.

Dilute reaction above 1:200 in H2O (Note: diluted reaction can be stored at -20)
Ligation Reaction:
Component
Amount (ul)
X 4 reactions
Cas9 Plasmid at 50ng/ul
2
8
Diluted guide oligos from step 4
2
10X Cutsmart Buffer
2
8
10mM DTT
1
4
10mM ATP
1
4
NEB BbsI (5U/ul)
1.25
5
NEB T4 DNA ligase
1
4
H20
9.75
39
TOTAL:
20
18ul +2ul oligo
Thermocycler Program: CRISPR Ligation
Cycling Conditions: [37⁰ for 5mins, 21⁰ for 5mins ] x 6 cycles
6.

Plasmid Safe Reaction:
Component
Ligation reaction from above
11
10X Plasmid Safe Buffer
1.5
10mM Plasmid Safe ATP Solution
1.5
Plasmidsafe Exonuclease
1
TOTAL:
15
Thermocycler Program: Plasmidsafe
Cycling Conditions: 37⁰ for 30mins, 70⁰ for 30mins
7.
8.

Amount (ul)

Proceed to transformation or store at -20⁰
Transformation:
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X 4 reactions
6
6
4
4ul + 11ul ligation rxn

a.
b.
c.
d.
e.
f.

Add 2ul of plasmidsafe reaction to 25ul of thawed NEB Turbo competent cells (NEB)
Incubate on ice 30mins
Heatshock at 42⁰ for 30 sec
Incubate on ice 5 mins
Add 750ul of SOC and incubate in shaker at 37⁰ for 1 hour
Dilute 1:3 and plate 60ul on LB amp plate
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DNA methylation detection via MSRE-qPCR
Reagents:
 HhaI (NEB R0139S)
 HaeIII (NEB R0108S)
 2X Syber Green Master Mix (Roche 04913914001 or Thermo Fisher A25742)
-Genomic DNA must be column extracted for complete HhaI digest
-Dilute genomic DNA to 10ng/ul; Need at least 20ul per run.
-Always run 50% and 0% methylation controls
-HaeIII is needed to control for melting differences due to different repeat lengths
# RXNs
Mock
H2O
Cutsmart
HaeIII (20u/ul)
HhaI (20u/ul)

x1

x

1
Digest
7.9
7.7
2
2
0.1
0.1
0
0.2
10ul MM + 10ul DNA (100ng)

x

37⁰ for 16hrs (overnight); 80⁰ for 20mins to inactivate enzymes
qPCR with Syber Green
CpG1: chr9:27574058-27574271; Primers: 5PC9 F + Out5PC9 R
CpG2: chr9:27,573,299-27,573,429; Primers: 2CpG DIG F + 2CpG DIG R (always unmethylated)
Reagent
Amount (ul)
2X Syber Green Mix 10
5uM Primer F
1.2
5uM Primer R
1.2
milliH2O
5.1
Digested DNA
2.5
17.5ul MM + 2.5ul DNA (12.5ng/reaction)
-Add MM to plate first in duplicates
-Add DNA and seal plate
-Run on Applied Biosystems Step One Plus qPCR machine (standard cycling for syber green
reagents)
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Chromatin immunoprecipitation from cell lines
Solutions Needed:











I)

1 M Tris-HCl pH 8 (6.05g for 50mL)
5 M NaCl (14.61g for 50mL)
0.5M EDTA (0.731g for 50mL)
Lysis Buffer (for 200mL): 0.5% SDS (10mL of 10% SDS), 10mM EDTA (0.584g), 50mM Tris/HCl pH 8 (1.21g)
ChiP dilution Buffer (for 200mL): 0.01% SDS (0.2mL of 10%), 1.1% TritonX (2.2mL), 1.2mM EDTA (0.07g), 16.7mM
Tris/HCl pH 8 (0.40g), 167mM NaCl (1.95g)
Low Salt Buffer (for 50mL): 0.1% SDS (0.5mL of 10%), 1% TritonX (0.5mL), 1.2mM EDTA, 16.7mM Tris/HCl pH 8,
150mM NaCl (0.44g)
High Salt Buffer (for 50mL): 0.1% SDS (0.5mL of 10%), 1% TritonX (0.5mL), 1.2mM EDTA, 16.7mM Tris/HCl pH 8,
500mM NaCl (1.46g)
LiCl Buffer (for 50mL): 0.25M LiCl (0.53g), 1% NP-40 (0.5mL), 1% sodium deoxycholate (0.5g), 1mM EDTA (0.1mL of
0.5M), 10mM Tris/HCl pH 8 (0.5mL of 1M)
Elution Buffer (for 50mL): 1% SDS (0.5mL), 50mM Tris/HCl pH 8 (2.5mL of 1M), 1mM EDTA (0.1mL of 0.5M)
BSA Blocking (for 50mL): 0.25g BSA, 1X PBS

Lysate Preparation and Crosslinking
1. Cells grown to 90% confluency in 10cm dishes (~8 million cells per dish)
2. Crosslinking: Aspirate media and carefully add 10mL media with 1% formaldehyde;
(270ul pf 37% formaldehyde stock per 10mL media)
3. Incubate for 10 mins at 37 degrees
4. Quench: Add 500μL 2.5 M Glycine directly to cells and incubate for 10 mins at 37 to
quench; color should change to yellow
5. Add 10mL cold 1X PBS to wash cells; scrape cells with cell scrapper and add to cold 15mL
conical
6. Pellet cells at 2,000 rpm for 5 mins at 4 degrees; aspirate liquid
7. Resuspend in 1.2mL cold ChIP lysis buffer (+ 1μL 1000X protease inhibitor)
8. Transfer 400μL of the cells + lysis buffer to bioruptor tubes (~2x106 cells per tube) for
sonication
9. Freeze lysates at -80, or incubate 10 mins on ice and proceed directly to sonication
10. Sonicate with bioruptor on high, 30 on, 30 off for 30 cycles total; After every 10 cycles,
spin for 30 sec max seed (20,000g), 4⁰ and vortex briefly.
11. After sonication, spin max speed for 10 mins, 4⁰; transfer and combine supernatant to
new chilled tubes
12. Take 100μL lysate from each sample for DNA analysis and freeze the remaining lysate at
-80.
13. Reverse cross-link the 100μL lysate by adding 2ul RNAse A (10mg/mL) and incubating at
37 for 30 mins; next add 1 ul proteinase K (20mg/mL) and incubate ON at 65⁰
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14. Isolate DNA from the 100μL lysate using Qiagen PCR purfication kit; elute in 50μL EB
buffer and nanodrop; Run 1-2ug of DNA on gel to determine sheer size; Optimal shear is
200-500bp.
II) Beads Preparation
Can use either agarose or Dyanabeads protein A
1. Vortex and pipette beads to resuspend
2. Add 30μL protein A beads/Dynabeads to 1.7mL tubes; one tube per IP or IgG control
3. Wash beads 2X with 500μL 0.5% BSA blocking solution
4. Resuspend in 50ul 0.5% BSA blocking solution
5. Add antibody to IP tubes (5-10μL for cell signaling antibodies; varies depending on
antibody)
6. Add 2μl IgG (of 1.14 mg/mL stock or ~ 2μg)
7. Incubate on rotator, 4⁰ for 5 hrs to overnight
8. Wash beads 2X with 250ul block solution and resuspend in 50μL BSA blocking solution
9. Dilute sonicated lysate with 5X ChiP dilution buffer; make enough for 20ug per IP/IgG
reaction plus at least 10% extra
10. Remove 10% of the volume of diluted lysate (2 μg DNA) for the input (one per sample),
store at 4⁰
11. Add volume of lysate corresponding to 20ug DNA (same volume for IP and IgG samples)
to the corresponding beads/antibody + BSA tubes
12. Incubate ON on rotor at 4⁰
III) ChiP Washes and Reverse Cross-linking
1. Pellet beads and discard supernatant
2. Add 1mL Low-salt wash buffer, incubate on rotor for 10 mins at 4⁰
3. Pellet beads and discard supernatant; Add 1mL of High Salt buffer, incubate on rotor, 10
min, 4⁰
4. Pellet beads and discard supernatant; Add 1mL of LiCl buffer, incubate on rotor, 10 min,
4⁰
5. Pellet beads and discard supernatant; Add 1mL of 1X TE buffer, incubate on rotor, 10
min, 4⁰
6. Spin briefly on microcentrifuge and place back on magnet to remove final bit of liquid
7. Elute samples from beads by adding 200μL Elution buffer, incubate at 65⁰ for 20 min
with shaking at 500rpm; flick tubes every 5 mins
8. Pellet beads and collect supernatant in new tubes
9. To inputs: add elution buffer to total 200ul
10. Add 8ul of 10mg/ml RNAse A to each sample and incubate for 1 hour at 37⁰
11. Add 3μl Proteinase K (20mg/mL), 8 μL 1M Tris-HCl, 8 μL 5M NaCl and 8 μL 0.25M EDTA
to all samples
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12. Incubate ON at 65⁰
13. Isolate DNA using Qiagen PCR purification kit; elute 2X with 50μL EB buffer
14. Perform q-PCR (10μl 2X SyberGreen, 1.2μL each primer, 4μL DNA, 3.6μL H2O per
reaction)
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Feeder Free iPSC culture
Coating Plates with Matrigel
 Matrigel is aliquotted in 150ul and 300ul at -20 C
 Thaw Matrigel for 30-45 mins at 4 C; Do not leave at RT
 Add 150ul to a maximum of 12mL of cold DMEM/F12 media or 300ul to a max of 24mL
media
o Can make more concentrated if need fewer wells
 Use cold pipet to transfer 1mL of media+matrigel to each well on a 6 well plate
 Swirl plates to make sure wells are fully coated and incubate at RT for 45-60 mins
Making mTeSR 1 Media
 Combine 400mL Base media with 100mL Supplement to make complete mTeSR 1 media
 Aliqout 25-50mL to keep at 4 C and wrap in foil to protect from light
o Can be used for 2 weeks
 Aliqout rest of media and freeze at -20 C
o Stable for 6 months
Thawing Cells
 Make wash media: Mix 12.5 mL of DMEM/F12 media with 12.5 mL mTesR1 media
 Let cells thaw in water bath
 Thaw ROCK inhibitor
 Add cells to 25mL of wash media
 Spin at 1,2000 rpm for 3 mins (Program 1 -> Enter -> Start)
 Vacuum off media from matrigel coated plates
 Check for cell pellet and vacuum off media
 Resuspend cells in 2mL mTesR1 media per well
 Add 1ul ROCK inhibitor per 5mL media and mix by pipetting
 Plate 2mL of cells per well
 Mix plates before putting in incubator
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Differentiation of iPSCs to NPCs
Necessary reagents:
Reagent
2-Mercaptoethanol

Supplier

Cat#

B27 Supplement

Fisher
Cell Center (Invitrogen)

21985-023
17504044

DMEM/F12

Cell Center (Invitrogen)

11320033

Glutamax Supplement

Cell Center (Invitrogen)

35050061

Human FGF2 (Basic)

PeproTech

N2 supplement

Cell Center (Invitrogen)

Neurobasal media

Cell Center(Invitrogen)

17502048
21103049

Dorsomorphin
MEM non-essential amino acids

Sigma
Cell Center (Invitrogen)

P5499-5MG
11140050

L-Glutamine

Cell Center (Invitrogen)

25030-024

Insulin (human)

Sigma (cell center)

I9278-5ML

Pencillin/Streptomyocin

Cell Center (Invitrogen)

SB431542

Fisher (Tocris)

15140122
161410

Matrigel

Corning

ROCK inhibitor Y27632

ATCC

Accutase
mTeSR1

StemCell Technologies
StemCell Technologies

100-18B

354277
ACS-3030
07920
05850

Media Recipes:

Component
DMEM/F12
GlutaMAX
N2 Supplement
Insulin
L-Glutamine
non-essential amino acids
2-Mercaptoethanol
Pen/Strept

N-2 Media
Stock Con.
1X
100X
100X
11.2mg/mL
200mM
10mM
55mM
10,000mg/mL

B-27 Media
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Final Con.
1X
1X
1X
5ug/mL
1mM
0.1mM
0.1mM
50mg/mL

Component
Neurobasal media
B27 Supplement
L-Glutamine
Pen/Strep

Stock Con.
1X
50x
200mM
10,000mg/mL

Final Con.
1X
1X
1mM
50mg/mL

Component
N-2 media
B-27 Media

Neural Maintenance Media (1:1 mix of N-2
and B-27 media)
Stock Con.
Final Con.
1X
1X
1X
1x

Component
Neural maintenance Media
SB431542
Dorsomorphin

Neural Induction Media - make fresh, lasts 5
days
Stock Con.
Final Con.
1X
1X
100mM
10uM
10mM
1uM

Component
Neural Maintenance Media
DMSO
FGF-2

Neural Freezing media - make fresh
Stock Con.
Final Con.
1X
1X
100%
10%
50ug/mL
0.02ug/mL

Protocol:
Day 0: Plating of iPSCs for Neural Induction
 Grow iPSCs to confluency in 10cm dishes with Mtser1
 Remove Mtser1 and add 4mL Accutase per 10 cm dish
 Incubate at 37⁰ for 6-8 mins until cell lift off plate
 Pipette up and down with a P1000 to break up clumps of cells, then add 4mL
DMEM
 Transfer to 15mL conical and pellet cells at 1,200 rpm for 3 mins
 Resuspend cells in 8mL of Mtser + Rocki (10uM final con.)
 Remove 50ul for counting and add to 50ul trypan blue; count cells
 Seed cells at 2x106 cells/well in a 6 well plate coated with matrigel (Note: this is
dependent on cell line; slowly growing lines may require higher density
seeding; cells should be a confluent monolayer the next day)
Day 1 – 6: Feed cells
 Cells should be 100% confluent before beginning induction
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Prepare Neural Induction Media by adding SB431542 (10uM final con.) and
Dorsomorphin (1uM final con.); Induction media should be prepared fresh every
5 days
Remove media, wash with 1mL of DMEM to remove dead cells
Add 2mL Neural Induction Media

Day 5: Passage #1 (1:2 split)
 By day 5, the cells should be extremely confluent and may even start to lift off the
plate
 Remove media and wash with 1 mL DMEM
 Add 1 mL accutase and incubate at 37⁰ for 6-8 mins or until cells detach
 Add 1 mL DMEM and break up cell clumps with P1000
 Pellet cells at 1,200 rpm for 3 mins
 Resuspend in Neural Induction Media and seed into new matrigel coated 6 well
dish; split cells 1:2, which will be ~1x106 cells/well
Day 6-7: Feed cells
 Feed cells with Neural induction media
 Cells should now undergo a morphological change to an epithelial like
appearance (e.g. polygonal and large rather than the small and round iPSCs)
Day 8: Passage #2 (1:3 or 1:2 split depending on cell line)
 Cells should be confluent again by day 8
 Repeat passaging as on day 5, but this time split 1:3 if they are a fast growing line
or 1:2 if they grow more slowly
 Wells can be pelleted for RNA extraction or used for seeding coverslips for IHC;
Oct4 expression should be very low and Pax6 should be high in day 8 NPCs
Day 9-11: Feed cells
 Continue feeding with Neural Induction Media each day
 Cells should now start to form neural rosettes structures, although they may not be
well defined
Day 12: Freezing of NPCs and switch to Neural Maintenance media
 NPCs can now be frozen down and used for future expansion to neurons
 Remove media and add 1mL accutase per well for 6-8 mins at 37⁰
 Add 1 mL media, pipette to break up clumps and transfer to conical tube
 Spin 1,200 rpm for 3 mins; remove media
 Resuspend in Neural Freezing media with freshly added FGF-2 and DMSO
 Freeze 1 mL per cryovial in Mr. Freezy at -80; transfer to liquid nitrogen the next
day
Day 13-20: NPC Expansion – SWITCH to Laminin Matrix
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After day 12, add 20ng/mL FGF-2 to the media for the next 4 days to promote
cell division of NPCs
After FGF-2 treatment, media can be changed every other day rather than every
day
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